



**Publication rate for funded studies from a major UK health research funder: a cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002521
Article Type:	Research
Date Submitted by the Author:	08-Jan-2013
Complete List of Authors:	Turner, Sheila; University of Southampton, NETSCC Wright, David; University of Southampton, NETSCC Maeso, Rebecca; University of Southampton, NETSCC Cook, Andrew; University of Southampton, Wessex Institute Milne, Ruairidh; University of Southampton, Wessex Institute
<b>Primary Subject Heading</b>:	Evidence based practice
Secondary Subject Heading:	Medical publishing and peer review
Keywords:	research waste, research funding, publication

SCHOLARONE™  
Manuscripts

Peer Review Only

## Title page

**Title:** Publication rate for funded studies from a major UK health research funder: a cohort study.

Turner S<sup>1a\*</sup>, Wright D<sup>1a</sup>, Maeso R<sup>2a</sup>, Cook A<sup>3b</sup> and Milne R<sup>4b</sup>.

<sup>a</sup>National Institute for Health Research  
Evaluation, Trials and Studies Coordinating Centre (NETSCC)  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

<sup>b</sup>Wessex Institute  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

\*Corresponding author, [s.turner@soton.ac.uk](mailto:s.turner@soton.ac.uk)  
Tel: +44(0)2380 595757 Fax: +44(0)2380 595639

<sup>1</sup>Senior research fellow; <sup>2</sup>Senior programme manager; <sup>3</sup>Consultant in Public Health Medicine and Fellow in Health Technology Assessment; <sup>4</sup>Director of the Wessex Institute and Head of NETSCC.

**Key words:** Health Technology Assessment, publication, research funding.

## Abstract

**Objectives:** This study aimed to investigate what percentage of NIHR HTA programme funded projects have published their final reports in the programme's journal Health Technology Assessment, and to explore reasons for non-publication.

**Design:** retrospective cohort study

**Setting:** Failure to publish findings from research is a significant area of research waste. It has previously been suggested that potentially over 50% of studies funded are never published.

**Participants:** All NIHR HTA projects with a planned submission date for their final report for publication in the journal series on or before 9th December 2011 were included.

**Primary and secondary outcome measures:** Projects were classified according to the type of research, whether they had published or not; and if not yet published, whether they would publish in the future or not. Reasons for non-publication were investigated.

**Results:** 628 projects were included: 561 (89.3%) had published a monograph; 39 (6.2%) were expected to publish a monograph; 13 (2.1%) were discontinued studies and would not publish; 13 (2.1%) submitted a report which did not lead to publication as a monograph; and 2 (0.3%) did not submit a report. Overall 95.5% of HTA studies either have published or will publish a monograph: 94% for those commissioned in 2002 or before and 98% for those commissioned after 2002.

Of the 28 projects for which there will be no report, the majority (22) were commissioned in 2002 or before. Reasons why projects failed to complete included: failure to recruit; issues concerning the organisation where the research was taking place; drug licensing issues; staffing issues; and access to data.

**Conclusions:** The percentage of HTA projects for which a monograph is published is high. The advantages of funding organisations requiring publication in their own journal include avoidance of publication bias and research waste; and enhancing accessibility of findings.

### Article summary

#### Article focus

- It has previously been suggested that potentially over 50% of biomedical studies funded are never published. Currently the literature on publication rates for funded studies is sparse.

#### Key messages

- This paper supplies data from a major UK funder of clinical trials (the NIHR HTA programme) showing that 98% of its funded studies will publish in its own MEDLINE indexed journal.
- Benefits of a journal series run by the funder including high percentages of studies publishing findings, the opportunity for complete reporting and avoidance of publication bias are highlighted.

#### Strengths and limitations

- We considered a large sample of projects from a major UK research funder, over a period of 18 years
- Studies from earlier phase trials were not represented in this study

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### Funding statement

This research was supported by the NIHR Evaluation, Trials and Studies Coordinating Centre through its Research on Research Programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Department of Health, or of NETSCC.

### Competing interests statement

The authors have no competing financial interests; however, all of the authors are employed by the University of Southampton to work at least part time for NETSCC and NETSCC's reputation rests substantially on having managed the HTA programme for the Department of Health for over 15 years.

In particular: RM is employed as the Head of NETSCC and has worked for NETSCC (and its predecessor organisation) in senior roles on and off since 1996. He was an editor of the Health Technology Assessment journal (1997-2007) and a founder editor for other journals in the new NIHR Journals Library (2011-12); AC has worked for the HTA programme since 2005; ST worked for the HTA programme 2005-2008.

### Introduction

It was stated by Chalmers and Glasziou (2009)<sup>1</sup> that worldwide, over US\$100 billion is invested per year in biomedical research. They went on to describe four stages at which waste of this resource may occur: choosing the wrong questions for research; doing studies that are unnecessary or poorly designed; failure to publish promptly or at all; and biased or unusable reports of research. This project responds primarily to the third stage of research waste identified; enabling accessible full publication. In their paper, Chalmers and Glasziou<sup>1</sup> suggested that potentially over 50% of clinical trials funded are never published in full. This data was obtained from a Cochrane review<sup>2</sup> which stated that "Less than half of all studies, and about 60% of randomized or controlled clinical trials, initially presented as summaries or abstracts at professional meetings are subsequently published as peer-reviewed journal articles".

It is vitally important that studies report in order to provide evidence to clinicians to inform practice, and policy makers to support them in decision making. There is currently a move towards open access to the data from publically funded research<sup>3,4</sup> in order to increase the returns on public investment; to increase transparency; to prevent duplication in research commissioning; to allow public scrutiny of the research process and inform patient and public decision making; and to make the results of trials available to the public including participants who have given their time to the study for public benefit.

It was also noted by Chalmers and Glasziou that publication bias leads to a systematic under reporting of studies with disappointing results, and that public access to the full results of all research remains an aspiration<sup>1</sup>. Other investigators have also found lower publication rates for studies with negative results or indefinite conclusions<sup>2,5-8</sup>. The NIHR Health Technology Assessment (HTA) programme commissions and funds primary research and evidence synthesis on the effectiveness, costs and broader impact of healthcare treatments and tests for those who plan,

1  
2  
3 provide or receive care in the NHS. It aspires to maximise return on investment by enabling, where  
4 possible, all funded projects to complete and publish, and maximising impact for money spent<sup>9</sup>.

5  
6 The HTA programme publishes a journal (Health Technology Assessment, known colloquially as the  
7 monograph series) which is available to all via the web and aims to publish a report for each project  
8 funded. The monograph is unique in that each publication focuses exclusively the final report of one  
9 study. Not only is publication encouraged, the agreement for the team to write and submit this final  
10 report is written into the contractual arrangement at the time of funding. The report is typically  
11 much longer than peer reviewed journal articles as teams are expected to publish full details of  
12 studies – essentially as an archive of the study; (irrespective of whether the results are positive,  
13 negative or indefinite), without limits on word count or length, in a high impact factor journal which  
14 is publically and freely available. This project aims to investigate the performance of the HTA  
15 programme by assessing what percentage of HTA projects are published in the monograph series,  
16 and if they are not published what are the reasons?  
17  
18  
19  
20  
21  
22

## 23 Methods

24  
25  
26 For this study we selected a cohort of HTA projects for which the planned date for submission of  
27 their draft final report (DFR) for monograph publication was on or before 9th December 2011. We  
28 identified these projects from a proprietary database system used to manage the HTA and other  
29 NIHR research programmes.  
30  
31

32 We excluded from the sample: projects for which the reports were supplementing monographs  
33 already published; projects that were prospectively not considered suitable for the publication of a  
34 monograph e.g. working papers for NIC or short briefing papers; and projects for which certain  
35 criteria needed to be met before the project commences e.g. projects relating to possible future  
36 H<sub>1</sub>N<sub>1</sub> pandemics.  
37  
38

39 To assure data quality, NETSCC staff with responsibility for the publication process independently  
40 checked the records for studies where there was no publication. Similarly where data indicated that  
41 no DFR had been received this information was again checked with the team which should have  
42 received it.  
43  
44

45 All projects were categorised as either: primary research (typically randomised controlled trials);  
46 secondary research (mainly systematic reviews); HTA Technology Assessment Reports (TARs) (which  
47 identify, assess and synthesise research evidence from a number of healthcare interventions,  
48 providing estimates of relative effectiveness and cost effectiveness of a range of interventions); or  
49 National Institute for health and Clinical Excellence (NICE) TARs (similar to HTA TARs but prepared  
50 specifically for NICE). Projects were also categorised as: (1) Projects for which a monograph has been  
51 published; (2) projects for which the DFR had been received but as yet there was no published  
52 monograph; (3) No DFR received and (4) project discontinued. The data were further sub-divided  
53 into those projects where the commissioning process started within the last 10 years (i.e. after 2002),  
54 and those where it began in 2002 or before.  
55  
56  
57  
58  
59  
60

For projects which had not yet published, we needed to know whether a report would eventually be produced. Projects in this category were considered by a staff member (LT) with experience in editorial processes and detailed knowledge of the projects concerned. They designated projects as either “will publish” or “will not publish”.

For projects which were not expected to publish, (or had been discontinued, or where no DFR had been received); we further investigated the reasons why by interrogating in-house electronic records and by referring to hard copy project files. For projects where no DFR had been received a web search and a search of internal records was conducted to see if the results of the studies had been published elsewhere.

## Results

Initial searches identified 642 projects (see Figure 1). Of these, 1 was excluded because it was a supplementary project following a monograph which had already been published; 3 because they related to potential future H<sub>1</sub>N<sub>1</sub> flu pandemics and required particular circumstances to occur before the project would begin; 1 as the report had been superseded by another; 5 as they had been included with another report under a different identification number. Four projects were not suitable for publication as monographs as they were very small and not suitable for publication alone; they had been commissioned to report by a different route; or were working papers for NICE. This left a cohort with a final total of 628 projects (201 primary research, 169 systematic reviews, 110 HTA TARs and 148 NICE TARs).

For 52 projects a DFR had been received but as yet there was no publication. After consultation with staff expert in this area, it was deemed that 39 of these would eventually publish and 13 would not (see Table 1).

**Table 1. DFR received, not yet published: “will publish” or” will not publish”**

Type of research	Will publish	Will not publish	Total number for which DFR rec'd but not yet published
Primary research	17	11	28
Systematic reviews	8	2	10
HTA TARs	8	0	8
NICE TARs	6	0	6
<b>TOTALS</b>	39	13	52

In total 561 projects had published a monograph, 2 studies had no DFR and 13 studies had been discontinued. For primary research studies, the reasons for discontinuation were mainly failure to recruit, e.g. in one case it was due to difficulties for the PI caused by reorganisation within NHS institutions. For the systematic reviews and TARS the reasons were either to do with drug licensing

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(NICE often requests TARs anticipating drug licencing, to inform future guidance, if the drug is not licensed there is no need for a review and NICE will cancel its request); reliance being placed on access to data being allowed by a third party who then would not release the data; or to issues around key staff leaving, or being unwell. A summary of results is given in Table 2.

For peer review only



**Table 2. Numbers of studies published and research type**

	PR	SR	HTA TAR	NICE TAR	Totals
<b>Published</b>	163	157	101	140	561 (89.3%)
<b>No DFR rec'd</b>	2	0	0	0	2 (0.3%)
<b>Discontinued studies</b>	8	2	1	2	13 (2.1%)
<b>DFR rec'd – will publish</b>	17	8	8	6	39 (6.2%)
<b>DRF rec'd – will not publish</b>	11	2	0	0	13 (2.1%)
<b>Totals</b>	<b>201</b>	<b>169</b>	<b>110</b>	<b>148</b>	<b>628 (100%)</b>

It was noticeable from the data that the majority of projects that did not publish were those commissioned early on in the history of the HTA programme. The data shows that the vast majority of projects for which there will be no publication in the HTA monograph series were commissioned in 2002 or before (see Table 3). There is a difference over time, where the percentage of projects that publish rises from 94% to 98% and the numbers of projects not completing or not publishing falls from 6% to 2% after 2002.

**Table 3. Percentages of projects commissioned either in 2002 or before, or after 2002; which do or do not publish in the HTA monograph series.**

	PR		SR		HTA TAR		NICE TAR		TOTALS	
	2002 and older	After 2002	2002 and older	After 2002	2002 and older	After 2002	2002 and older	After 2002	2002 and older	After 2002
<b>Published or will publish</b>	125 (87%)	55 (96%)	105 (97%)	60 (98%)	27 (100%)	82 (99%)	69 (100%)	77 (97%)	326/348 (94%)	274/280 (98%)
<b>No DFR rec'd/Will not publish/ Discontinued studies</b>	19 (13%)	2 (4%)	3 (3%)	1 (2%)	0 (0%)	1 (1%)	0 (0%)	2 (3%)	22/348 (6%)	6/280 (2%)
	<b>144</b>	<b>57</b>	<b>108</b>	<b>61</b>	<b>27</b>	<b>83</b>	<b>69</b>	<b>79</b>	<b>348</b>	<b>280</b>
<b>Totals</b>	<b>201</b>		<b>169</b>		<b>110</b>		<b>148</b>		<b>628</b>	

More than half of the projects which will not publish (6 out of the 11 primary research studies and 1 of the 2 systematic reviews), and both projects that did not submit a DFR, were commissioned in 1993. This was before the HTA programme had the current processes and procedures in place which have developed as the programme has matured, and predates the existence of the National Coordinating Centre for Health Technology Assessment (NCCHTA) by three years. In fact some of the very early projects were not commissioned by the HTA programme; they were transferred over from

a previous funding stream. The results of the investigations as to why no monograph was to be published for projects for which a DFR had been submitted, are shown in Table 4. In the majority of cases (77%), this was because the draft report was of insufficient quality for publication as a monograph. Currently the HTA programme operates editorial processes which work together with authors to bring reports up to publishable quality. Most of the projects (85%) which were not published as monographs were primary research projects.

**Table 4. Reasons why no monograph is to be published for projects for which a DFR had been submitted.**

	<b>Draft final report (DFR) of insufficient quality</b>	<b>Study was only a pilot and was not therefore published as a monograph</b>	<b>Project commissioned in 1993, no records available</b>	<b>Totals</b>
<b>Primary research</b>	9 (69%)	2 (15%)	0	<b>11 (85%)</b>
<b>Systematic reviews</b>	1 (8%)	0	1 (8%)	<b>2 (15%)</b>
<b>Totals</b>	<b>10 (77%)</b>	<b>2 (15%)</b>	<b>1 (8%)</b>	<b>13</b>

Considering the 2 projects where no DFR had been received; searches identified one peer reviewed paper and for the 9 primary research studies where the DFRs received were of insufficient quality to publish as monographs, 6 of these projects had also published elsewhere in peer reviewed journals.

## Discussion

Overall the percentage of projects commissioned by the HTA programme which publish in its journal is high, for those commissioned in 2002 or before 94% published, for those commissioned after 2002 the figure rises to 98%. This number is well in excess of the figure of 50% quoted by Chalmers and Glasziou<sup>1</sup> although it must be born in mind that their data related to studies initially presented as summaries or abstracts at professional meetings (which may include pilot or feasibility studies which do not progress to full studies), rather than commissioned projects, and so is likely to overestimate the publication rate. This rate is also higher than some other funders, for the NIH after a median of 51 months after trial completion, a third of trials remained unpublished<sup>10</sup>. Little has been published by other research funders on publication rates of funded studies.

The strengths of this study were that it considered a large sample of projects from a major UK research funder, over a period of 18 years, encompassing a variety of research methodologies.

1  
2  
3 Additionally in depth data was available on most of the projects to enable us to understand the  
4 reasons behind the statistical evidence. Weaknesses include: primary research projects considered  
5 within the cohort all related to a certain stage in health research and had to be within the remit of  
6 the Health Technology Assessment programme which typically funds late phase clinical trials,  
7 investigating the effectiveness and cost effectiveness of a diverse range of health technologies  
8 (which may include drugs, devices, physical therapies, talking therapies, public health interventions,  
9 surgical procedures etc.). Consequently studies from earlier phase trials were not represented in this  
10 study. This work does not specifically consider the length of time to publication which is also  
11 pertinent<sup>11</sup>; however this question is being addressed in another study currently underway.  
12  
13  
14

15 It is highly desirable that projects should publish final results for completed studies and the data  
16 presented here demonstrate a high level of project completion and publication. This is likely to be  
17 attributable to 3 particular elements of the programme: 1) selection of the right projects at the  
18 beginning, through using a process to identify research questions of the most pressing interest to  
19 clinicians in the NHS. This also encourages buy-in from investigators and participants who are  
20 committed to answering important questions. 2) A robust monitoring process which can anticipate  
21 which projects might fail and help to correct them. The majority of projects which have not  
22 published or will not publish were commissioned very early in the history of the HTA programme.  
23 Current monitoring processes carefully monitor progress of projects, and action is taken to assist  
24 studies struggling with problems such as recruitment. It is likely that the current processes of the  
25 HTA programme for both commissioning and monitoring have had a positive effect on the  
26 monograph publication rate.  
27  
28  
29

30 Element 3) is the existence of the Health Technology Assessment journal. The high publication rate –  
31 a proxy for converting research funding into useful and accessible knowledge- demonstrates the  
32 benefits of such a system. Not only are the teams offered the opportunity and the space to publish  
33 studies in full, it is part of the contractual arrangement for funding. The journal publishes almost all  
34 projects regardless of results, thus minimising publication bias. Some studies elect to publish interim  
35 results in peer reviewed journals, however, it has been noted that the direction of effects reported  
36 in interim analyses and subsequent final analyses can vary<sup>8,12</sup>, the monograph series publishes final  
37 results in full. Teams associated with projects for which no monograph is to be published are  
38 strongly encouraged by the HTA programme to publish in other journals. Of the two projects for  
39 which no DFR was submitted; one had published a peer reviewed paper elsewhere; and of the 9  
40 primary studies for which no monograph was to be published 6 had published peer reviewed papers  
41 elsewhere. This would indicate that potential waste of resource had been minimised as at least  
42 some of the findings had been disseminated.  
43  
44  
45  
46

47 It could be an interesting area for future research to compare the findings of this study which has  
48 used data from the HTA programme with data from other funding streams or organisations, both  
49 within the UK and internationally.  
50  
51

52 Recommendations for future commissioning would include a requirement for funded projects to  
53 publish reports of final findings and for funders to facilitate this process.  
54  
55  
56  
57  
58  
59  
60

### Acknowledgements

The authors wish to acknowledge Liz Trelvelick for help in determining whether or not projects were likely to publish in the future.

### Abbreviations

HTA: Health Technology Assessment

TAR: Technology Assessment Report

### Authors' contributions

The study was conceived and designed by ST, DW, RM, BM and AC, and undertaken by ST; ST led the writing guided by DW, AC and RM. All authors read and approved the final manuscript.


### Reference List

1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *The Lancet* 2009;**374**:86-9.
2. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. *Cochrane Database of Systematic Reviews* 2007;**2**.
3. OECD Principles and Guidelines for Access to Research Data from Public Funding. Organisation for Economic Co-operation and Development . 2007.
4. National Institutes of Health Public Access. <http://publicaccess.nih.gov/> . 2012.
5. Krzyzanowska M, Pintilie M, Tannock I. Factors associated with failure to publish large randomized trials presented at an oncology meeting. *JAMA* 2003;**290**:495-501.
6. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess* 2010;**14**.
7. Stern JM, Simes JR. Publication bias: evidence of delayed publication in a cohort study of clinical projects. *British Medical Journal* 1997;**315**:640-5.
8. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database of Systematic Reviews* 2009;Art. No.: MR000006. DOI: 10.1002/14651858.MR000006.pub3.
9. Hanney S, Buxton M, Green C, et al. An assessment of the impact of the NHS Health Technology Assessment Programme. *Health Technol Assess* 2007;**11**:1-200.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
10. Ross JS, Tse T, Zarin DA, et al. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. *BMJ* 2011;**344**.
11. Takeda A, Loveman E, Harris P, et al. Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review. *Health Technol Assess* 2010;**12**.
12. Harris P, Takeda A, Loveman E, et al. Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias. *International Journal of Technology Assessment in Health Care* 2010;**26**:110-6.

For peer review only

Figure 1. Flow diagram of projects included in study



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



**Publication rate for funded studies from a major UK health research funder: a cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002521.R1
Article Type:	Research
Date Submitted by the Author:	22-Mar-2013
Complete List of Authors:	Turner, Sheila; University of Southampton, NETSCC Wright, David; University of Southampton, NETSCC Maeso, Rebecca; University of Southampton, NETSCC Cook, Andrew; University of Southampton, Wessex Institute Milne, Ruairidh; University of Southampton, Wessex Institute
<b>Primary Subject Heading</b>:	Evidence based practice
Secondary Subject Heading:	Medical publishing and peer review
Keywords:	research waste, research funding, publication

SCHOLARONE™  
Manuscripts

Peer Review Only



## Title page

**Title:** Publication rate for funded studies from a major UK health research funder: a cohort study.

Turner S<sup>1a\*</sup>, Wright D<sup>1a</sup>, Maeso R<sup>2a</sup>, Cook A<sup>3b</sup> and Milne R<sup>4b</sup>.

<sup>a</sup>National Institute for Health Research  
Evaluation, Trials and Studies Coordinating Centre (NETSCC)  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

<sup>b</sup>Wessex Institute  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

\*Corresponding author, [s.turner@soton.ac.uk](mailto:s.turner@soton.ac.uk)  
Tel: +44(0)2380 595757 Fax: +44(0)2380 595639

<sup>1</sup>Senior research fellow; <sup>2</sup>Senior programme manager; <sup>3</sup>Consultant in Public Health Medicine and Fellow in Health Technology Assessment; <sup>4</sup>Director of the Wessex Institute and Head of NETSCC.

**Key words:** Health Technology Assessment, publication, research funding.

## Abstract

**Objectives:** This study aimed to investigate what percentage of NIHR Health Technology Assessment (HTA) Programme funded projects have published their final reports in the programme's journal Health Technology Assessment, and to explore reasons for non-publication.

**Design:** retrospective cohort study

**Setting:** Failure to publish findings from research is a significant area of research waste. It has previously been suggested that potentially over 50% of studies funded are never published.

**Participants:** All NIHR HTA projects with a planned submission date for their final report for publication in the journal series on or before 9th December 2011 were included.

**Primary and secondary outcome measures:** Projects were classified according to the type of research, whether they had published or not; and if not yet published, whether they would publish in the future or not. Reasons for non-publication were investigated.

**Results:** 628 projects were included: 582 (92.7%) had published a monograph; 19 (3.0%) were expected to publish a monograph; 13 (2.1%) were discontinued studies and would not publish; 12 (1.9%) submitted a report which did not lead to publication as a monograph; and 2 (0.3%) did not submit a report. Overall 95.5% of HTA studies either have published or will publish a monograph: 94% for those commissioned in 2002 or before and 98% for those commissioned after 2002.

Of the 27 projects for which there will be no report, the majority (21) were commissioned in 2002 or before. Reasons why projects failed to complete included: failure to recruit; issues concerning the organisation where the research was taking place; drug licensing issues; staffing issues; and access to data.

**Conclusions:** The percentage of HTA projects for which a monograph is published is high. The advantages of funding organisations requiring publication in their own journal include avoidance of publication bias and research waste; and enhancing accessibility of findings.

### Article summary

#### Article focus

- It has previously been suggested that potentially over 50% of biomedical studies funded are never published. Currently the literature on publication rates for funded studies is sparse.

#### Key messages

- This paper supplies data from a major UK funder of clinical trials (the NIHR HTA Programme) showing that 98% of its funded studies will publish in its own MEDLINE indexed journal.
- Benefits of a journal series run by the funder including high percentages of studies publishing findings, the opportunity for complete reporting and avoidance of publication bias are highlighted.

#### Strengths and limitations

- We considered a large sample of projects from a major UK research funder, over a period of 18 years
- Studies from earlier phase trials were not represented in this study

### Funding statement

This research was supported by the NIHR Evaluation, Trials and Studies Coordinating Centre through its Research on Research programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Department of Health, or of NETSCC.

### Competing interests statement

The authors have no competing financial interests; however, all of the authors are employed by the University of Southampton to work at least part time for NETSCC and NETSCC's reputation rests substantially on having managed the HTA Programme for the Department of Health for over 15 years.

In particular: RM is employed as the Head of NETSCC and has worked for NETSCC (and its predecessor organisation) in senior roles on and off since 1996. He was an editor of the Health Technology Assessment journal (1997-2007) and a founder editor for other journals in the new NIHR Journals Library (2011-12); AC has worked for the HTA Programme since 2005; ST worked for the HTA Programme 2005-2008.

### Study approval

This study did not require study ethics approval; it did not involve patients or clinical data.

## Introduction

It was stated by Chalmers and Glasziou (2009)<sup>1</sup> that worldwide, over US\$100 billion is invested per year in biomedical research. They went on to describe four stages at which waste of this resource may occur: choosing the wrong questions for research; doing studies that are unnecessary or poorly designed; failure to publish promptly or at all; and biased or unusable reports of research. This project responds primarily to the third stage of research waste identified; enabling accessible full publication. In their paper, Chalmers and Glasziou<sup>1</sup> suggested that potentially over 50% of clinical trials funded are never published in full. This data was obtained from a Cochrane review<sup>2</sup> which stated that "Less than half of all studies, and about 60% of randomized or controlled clinical trials, initially presented as summaries or abstracts at professional meetings are subsequently published as peer-reviewed journal articles".

It is vitally important that studies report in order to provide evidence to clinicians to inform practice, and policy makers to support them in decision making. There is currently a move towards open access to the data from publically funded research<sup>3,4</sup> in order to increase the returns on public investment; to increase transparency; to prevent duplication in research commissioning; to allow public scrutiny of the research process and inform patient and public decision making; and to make the results of trials available to the public including participants who have given their time to the study for public benefit.

It was also noted by Chalmers and Glasziou that publication bias leads to a systematic under reporting of studies with disappointing results, and that public access to the full results of all research remains an aspiration<sup>1</sup>. Other investigators have also found lower publication rates for

1  
2  
3 studies with negative results or indefinite conclusions<sup>2,5-8</sup>. The National Institute for Health Research  
4 (NIHR) Health Technology Assessment (HTA) Programme commissions and funds primary research  
5 and evidence synthesis on the effectiveness, costs and broader impact of healthcare treatments and  
6 tests for those who plan, provide or receive care in the NHS. It aspires to maximise return on  
7 investment by enabling, where possible, all funded projects to complete and publish, and  
8 maximising impact for money spent<sup>9</sup>.

9  
10  
11 The HTA Programme publishes a journal (Health Technology Assessment, known colloquially as the  
12 monograph series) which is available to all via the web and aims to publish a report for each project  
13 funded. The monograph is unique in that each publication focuses exclusively the final report of one  
14 study. Not only is publication encouraged, the agreement for the team to write and submit this final  
15 report is written into the contractual arrangement at the time of funding. The report is typically  
16 much longer than peer reviewed journal articles as teams are expected to publish full details of  
17 studies (such as a full description of the intervention) – essentially as an archive of the study;  
18 (irrespective of whether the results are positive, negative or indefinite), without limits on word  
19 count or length, in a high impact factor journal which is publically and freely available. Authors are  
20 also encouraged to publish elsewhere to broaden dissemination of their findings, and there are  
21 other processes for the dissemination of Technology Assessment Reports. This project aims to  
22 investigate the performance of the HTA Programme by assessing what percentage of HTA projects  
23 are published in the monograph series, and if they are not published what are the reasons?  
24  
25  
26  
27  
28  
29

## 30 **Methods**

31  
32  
33 For this study we selected a cohort of HTA projects for which the planned date for submission of  
34 their draft final report (DFR) for monograph publication was on or before 9th December 2011. We  
35 identified these projects from a proprietary database system used to manage the HTA and other  
36 NIHR research programmes.  
37  
38

39 We excluded from the sample: projects for which the reports were supplementing monographs  
40 already published; projects that were prospectively not considered suitable for the publication of a  
41 monograph e.g. working papers for National Institute for health and Clinical Excellence (NICE) or  
42 short briefing papers; and projects for which certain criteria needed to be met before the project  
43 commences e.g. projects relating to possible future H<sub>1</sub>N<sub>1</sub> pandemics.  
44  
45

46 To assure data quality, NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) staff with  
47 responsibility for the publication process independently checked the records for studies where there  
48 was no publication. Similarly where data indicated that no DFR had been received this information  
49 was again checked with the team which should have received it.  
50  
51

52 All projects were categorised as either: primary research (typically randomised controlled trials);  
53 secondary research (mainly systematic reviews); HTA Technology Assessment Reports (TARs) (which  
54 identify, assess and synthesise research evidence from a number of healthcare interventions,  
55 providing estimates of relative effectiveness and cost effectiveness of a range of interventions); or  
56 NICE TARs (similar to HTA TARs but prepared specifically for NICE). Projects were also categorised as:  
57  
58  
59  
60

1  
2  
3 (1) Projects for which a monograph has been published; (2) projects for which the DFR had been  
4 received but as yet there was no published monograph; (3) No DFR received and (4) project  
5 discontinued. The data were further sub-divided into those projects where the commissioning  
6 process started within the last 10 years (i.e. after 2002), and those where it began in 2002 or before.  
7  
8

9 When projects publish in the monograph series the draft final reports go through an editorial review  
10 process which is conducted between the editors, reviewers and authors. Reports are published in  
11 the HTA journal series if they are of a sufficiently high scientific quality as assessed by the referees  
12 and editors<sup>10</sup>. For projects which had not yet published, we needed to know whether a report would  
13 eventually be produced. Projects in this category were considered by a staff member (LT) with  
14 experience in editorial processes, detailed knowledge of the projects concerned and knowledge of  
15 editorial decisions. They designated projects as either “will publish” or “will not publish”. This  
16 judgement was made using the following criteria. If at the end of the editorial process the editorial  
17 board of the HTA journal had deemed the report to be of “insufficient quality” to publish, this report  
18 was recorded as “will not publish”. If a report has been deemed as of sufficient quality to publish this  
19 was recorded as “will publish”. Data for “published” “will publish” or “will not publish” was originally  
20 obtained in July 2012 and updated on 8<sup>th</sup> March 2013. Each project was counted as one entity and  
21 the data were analysed by the calculation of percentages.  
22  
23  
24

25 For projects which were not expected to publish, (or had been discontinued, or where no DFR had  
26 been received); we further investigated the reasons why by interrogating in-house electronic records  
27 and by referring to hard copy project files which contained detailed records of correspondence with  
28 the authors, at the time when the report was due. For projects where no DFR had been received a  
29 web search (searching Medline and Google scholar using authors’ names and key words); and a  
30 search of internal records was conducted to see if the results of the studies had been published  
31 elsewhere.  
32  
33  
34

## 35 Results

36  
37  
38 Initial searches identified 642 projects (see Figure 1). Of these, 1 was excluded because it was a  
39 supplementary project following a monograph which had already been published; 3 because they  
40 related to potential future H<sub>1</sub>N<sub>1</sub> flu pandemics and required particular circumstances to occur before  
41 the project would begin; 1 as the report had been superseded by another; 5 as they had been  
42 included with another report under a different identification number. Four projects were not  
43 suitable for publication as monographs as they were very small and not suitable for publication  
44 alone; they had been commissioned to report by a different route; or were working papers for NICE.  
45 This left a cohort with a final total of 628 projects (201 primary research, 169 systematic reviews,  
46 110 HTA TARs and 148 NICE TARs).  
47  
48  
49

50 For 31 projects a DFR had been received but as yet there was no publication. After consultation with  
51 staff expert in this area, it was deemed that 19 of these would eventually publish and 12 would not  
52 (see Table 1). By March 2013 all of the 19 reports expected to publish were with the publisher and  
53 had been assigned dates by which it was anticipated that they would publish.  
54  
55  
56  
57  
58  
59  
60

**Table 1. DFR received, not yet published: “will publish” or “will not publish”**

Type of research	Will publish	Will not publish	Total number for which DFR rec'd but not yet published
Primary research	9	10	19
Systematic reviews	2	2	4
HTA TARs	4	0	4
NICE TARs	4	0	4
<b>TOTALS</b>	<b>19</b>	<b>12</b>	<b>31</b>

In total 582 projects had published a monograph, 2 studies had no DFR and 13 studies had been discontinued (see Table 2). For primary research studies, the reasons for discontinuation were mainly failure to recruit, e.g. in one case it was due to difficulties for the principal investigator (PI) caused by reorganisation within NHS institutions. For the systematic reviews and TARs the reasons were either to do with drug licensing (NICE often requests TARs anticipating drug licencing, to inform future guidance, if subsequently the drug is not licensed, there is no need for a review, and NICE will cancel its request consequently there will be no publication). Other reasons for discontinuation of studies were: reliance being placed on access to data being allowed by a third party who then would not release the data; and issues around key staff leaving, or being unwell. A summary of results is given in Table 2.

**Table 2. Numbers of studies published and research type**

	PR	SR	HTA TAR	NICE TAR	Totals
<b>Published</b>	172	163	105	142	582 (92.7%)
<b>No DFR rec'd</b>	2	0	0	0	2 (0.3%)
<b>Discontinued studies</b>	8	2	1	2	13 (2.1%)
<b>DFR rec'd – will publish</b>	9	2	4	4	19 (3.0%)
<b>DFR rec'd – will not publish</b>	10	2	0	0	12 (1.9%)
<b>Totals</b>	<b>201</b>	<b>169</b>	<b>110</b>	<b>148</b>	<b>628 (100%)</b>

It was noticeable from the data that the majority of projects that did not publish were those commissioned early on in the history of the HTA Programme. The data shows that the vast majority of projects for which there will be no publication in the HTA monograph series were commissioned in 2002 or before (see Figure 2). There is a difference over time, where the percentage of projects

that publish rises from 94% to 98% and the numbers of projects not completing or not publishing falls from 6% to 2% after 2002.

More than half of the projects which will not publish (6 out of the 11 primary research studies and 1 of the 2 systematic reviews), and both projects that did not submit a DFR, were commissioned in 1993. This was before the HTA Programme had the current processes and procedures in place which have developed as the programme has matured. The results of the investigations as to why no monograph was to be published for projects for which a DFR had been submitted, are shown in Table 3. In the majority of cases (77%), this was because the draft report was of insufficient quality for publication as a monograph. Currently the HTA Programme operates editorial processes which work together with authors to bring reports up to publishable quality. For one project commissioned in 1993, we were unable to locate the paper files and so were unable to determine the reasons for non-publication. Most of the projects (85%) which were not published as monographs were primary research projects.

**Table 3. Reasons why no monograph is to be published for projects for which a DFR had been submitted.**

	<b>Draft final report (DFR) of insufficient quality</b>	<b>Study was only a pilot and was not therefore published as a monograph</b>	<b>Project commissioned in 1993, no records available</b>	<b>Totals</b>
<b>Primary research</b>	9 (69%)	2 (15%)	0	<b>11 (85%)</b>
<b>Systematic reviews</b>	1 (8%)	0	1 (8%)	<b>2 (15%)</b>
<b>Totals</b>	<b>10 (77%)</b>	<b>2 (15%)</b>	<b>1 (8%)</b>	<b>13</b>

Considering the 2 projects where no DFR had been received; searches identified one peer reviewed paper. Nine of the primary research studies where the DFRs received were of insufficient quality to publish as monographs, 6 of these projects had also published elsewhere in peer reviewed journals. Whether or not a draft final report is deemed to be of "insufficient quality" to publish is a judgement made by the editorial board of the HTA journal series. A monograph is expected to cover all aspects of the study concerned in detail (average word count approx. 50,000 words), in contrast journal articles are much shorter (approx. 3,000 words), less detailed, and covering only certain aspects of the study. The judgement concerning whether a pilot study can be published as a "stand alone" monograph, or possibly together with another study as a combined monograph, is made by the editorial board.

## Discussion

Overall the percentage of projects commissioned by the HTA Programme which publish in its journal is high, for those commissioned in 2002 or before 94% published, for those commissioned after 2002 the figure rises to 98%. This number is well in excess of the figure of 50% quoted by Chalmers and Glasziou<sup>1</sup> although it must be born in mind that their data related to studies initially presented as summaries or abstracts at professional meetings (which may include pilot or feasibility studies which do not progress to full studies), rather than commissioned projects, and so is likely to overestimate the publication rate. This rate is also higher than some other funders, for the NIH after a median of 51 months after trial completion, a third of trials remained unpublished<sup>11</sup>.

The strengths of this study were that it considered a large sample of projects from a major UK research funder, over a period of 18 years, encompassing a variety of research methodologies. Additionally in depth data were available on most of the projects to enable us to understand the reasons behind the statistical evidence. Weaknesses include: primary research projects considered within the cohort all related to a certain stage in health research and had to be within the remit of the Health Technology Assessment Programme which typically funds late phase clinical trials, investigating the effectiveness and cost effectiveness of a diverse range of health technologies (which may include drugs, devices, physical therapies, talking therapies, public health interventions, surgical procedures etc.). Consequently studies from earlier phase trials were not represented in this study. This work does not specifically consider the length of time to publication which is also pertinent<sup>12</sup>; however this question is being addressed in another study currently underway.

It is highly desirable that projects should publish final results for completed studies and the data presented here demonstrate a high level of project completion and publication. This is likely to be attributable to 3 particular elements of the programme: 1) selection of the right projects at the beginning, through using a “needs led” process to identify research questions of the most pressing interest to clinicians in the NHS. This also encourages buy-in from investigators and participants who are committed to answering important questions. 2) A robust monitoring process which assists with timely delivery, budgets, etc.; and which can anticipate which projects might fail and help to correct problems as they arise. The majority of projects which have not published or will not publish were commissioned very early in the history of the HTA Programme. Current monitoring processes carefully monitor progress of projects, and action is taken to assist studies struggling with problems such as recruitment. It is likely that the current processes of the HTA Programme for both commissioning and monitoring have had a positive effect on the monograph publication rate.

Element 3) is the existence of the Health Technology Assessment journal. The high publication rate – a proxy for converting research funding into useful and accessible knowledge- demonstrates the benefits of such a system. Not only are the teams offered the opportunity and the space to publish studies in full, it is part of the contractual arrangement for funding and a proportion of funds are with-held until the report has been received. The journal publishes almost all projects regardless of results, thus minimising publication bias. Authors are also encouraged to publish in other peer reviewed journals to increase dissemination, however, the shorter length of these articles does not allow for the reporting of the detail presented in the monographs e.g. detailed descriptions of the intervention. Some studies elect to publish interim results in peer reviewed journals, however, it has



1  
2  
3 been noted that the direction of effects reported in interim analyses and subsequent final analyses  
4 can vary<sup>8;13</sup>, the monograph series publishes final results in full. Teams associated with projects for  
5 which no monograph is to be published are strongly encouraged by the HTA Programme to publish  
6 in other journals. Of the two projects for which no DFR was submitted; one had published a peer  
7 reviewed paper elsewhere; and of the 9 primary studies for which no monograph was to be  
8 published 6 had published peer reviewed papers elsewhere. This would indicate that potential waste  
9 of resource had been minimised as at least some of the findings had been disseminated. The  
10 generalisability of these findings would only relate directly to another funding system with an in  
11 house journal, but the general principles of encouraging and facilitating publication would be  
12 generalisable to all funders.  
13  
14

15  
16 Interesting areas for future research could be: to compare the findings of this study which has used  
17 data from the HTA Programme with data from other funding streams or organisations, both within  
18 the UK and internationally; and an investigation of the dissemination profile of HTA projects in terms  
19 of journal publications and publically accessible reports.  
20  
21

22 Recommendations for future commissioning would include a requirement for funded projects to  
23 publish reports of final findings and for funders to facilitate this process.  
24  
25  
26  
27  
28  
29  
30  
31

### 32 **Acknowledgements**

33 The authors wish to acknowledge Liz Trelvelick for help in determining whether or not projects were  
34 likely to publish in the future.  
35  
36

### 37 **Abbreviations**

38  
39 HTA: Health Technology Assessment  
40 TAR: Technology Assessment Report  
41  
42

### 43 **Authors' contributions**


44  
45 The study was conceived and designed by ST, DW, RM, BM and AC, and undertaken by ST; ST led the  
46 writing guided by DW, AC and RM. All authors read and approved the final manuscript.  
47  
48  
49  
50

### 51 **Reference List**


- 52  
53  
54 1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence.  
55 *The Lancet* 2009;**374**:86-9.  
56  
57  
58  
59  
60

- 1
- 2
- 3 2. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. *Cochrane Database of Systematic Reviews* 2007;**2**.
- 4
- 5
- 6 3. OECD Principles and Guidelines for Access to Research Data from Public Funding. Organisation
- 7 for Economic Co-operation and Development . 2007.
- 8
- 9
- 10 4. National Institutes of Health Public Access. <http://publicaccess.nih.gov/> . 2012.
- 11 Ref Type: Generic
- 12
- 13 5. Krzyzanowska M, Pintilie M, Tannock I. Factors associated with failure to publish large
- 14 randomized trials presented at an oncology meeting. *JAMA* 2003;**290**:495-501.
- 15
- 16 6. Song F, Parekh S, Hooper L, Loke YK, Ryder J. Dissemination and publication of research
- 17 findings: an updated review of related biases. *Health Technol Assess* 2010;**14**.
- 18
- 19 7. Stern JM, Simes JR. Publication bias: evidence of delayed publication in a cohort study of
- 20 clinical projects. *British Medical Journal* 1997;**315**:640-5.
- 21
- 22 8. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due
- 23 to statistical significance or direction of trial results. *Cochrane Database of Systematic Reviews*
- 24 2009;Art. No.: MR000006. DOI: 10.1002/14651858.MR000006.pub3.
- 25
- 26 9. Hanney S, Buxton M, Green C, Coulson D, Raftery J. An assessment of the impact of the NHS
- 27 Health Technology Assessment Programme. *Health Technol Assess* 2007;**11**:1-200.
- 28
- 29
- 30 10. HTA Journal. Health Technology Assessment website. 2013.
- 31
- 32
- 33 11. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM *et al*. Publication of NIH funded trials
- 34 registered in ClinicalTrials.gov: cross sectional analysis. *BMJ* 2011;**344**.
- 35
- 36 12. Takeda A, Loveman E, Harris P, Hartwell D, Welch K. Time to full publication of studies of anti-
- 37 cancer medicines for breast cancer and the potential for publication bias: a short systematic
- 38 review. *Health Technol Assess* 2010;**12**.
- 39
- 40 13. Harris P, Takeda A, Loveman E, Hartwell D. Time to full publication of studies of anticancer
- 41 drugs for breast cancer, and the potential for publication bias. *International Journal of*
- 42 *Technology Assessment in Health Care* 2010;**26**:110-6.
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1. Flow diagram of projects included in study



**Figure 2 Percentages of projects commissioned either in 2002 or before, or after 2002; which do or do not publish in the HTA monograph series.**



CONFIDENTIAL FOR REVIEW ONLY

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Title page

**Title:** Publication rate for funded studies from a major UK health research funder: a cohort study.

Turner S<sup>1a\*</sup>, Wright D<sup>1a</sup>, Maeso R<sup>2a</sup>, Cook A<sup>3b</sup> and Milne R<sup>4b</sup>.

<sup>a</sup>National Institute for Health Research  
Evaluation, Trials and Studies Coordinating Centre (NETSCC)  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

<sup>b</sup>Wessex Institute  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

\*Corresponding author, [s.turner@soton.ac.uk](mailto:s.turner@soton.ac.uk)  
Tel: +44(0)2380 595757 Fax: +44(0)2380 595639

<sup>1</sup>Senior research fellow; <sup>2</sup>Senior programme manager; <sup>3</sup>Consultant in Public Health Medicine and Fellow in Health Technology Assessment; <sup>4</sup>Director of the Wessex Institute and Head of NETSCC.

**Key words:** Health Technology Assessment, publication, research funding.

## Abstract

**Objectives:** This study aimed to investigate what percentage of NIHR [Health Technology Assessment \(HTA\) Programme](#) funded projects have published their final reports in the programme's journal Health Technology Assessment, and to explore reasons for non-publication.

**Design:** retrospective cohort study

**Setting:** Failure to publish findings from research is a significant area of research waste. It has previously been suggested that potentially over 50% of studies funded are never published.

**Participants:** All NIHR HTA projects with a planned submission date for their final report for publication in the journal series on or before 9th December 2011 were included.

**Primary and secondary outcome measures:** Projects were classified according to the type of research, whether they had published or not; and if not yet published, whether they would publish in the future or not. Reasons for non-publication were investigated.

**Results:** 628 projects were included: 582 (92.7%) had published a monograph; 319 (3.06%) were expected to publish a monograph; 13 (2.1%) were discontinued studies and would not publish; 132 (1.92%) submitted a report which did not lead to publication as a monograph; and 2 (0.3%) did not submit a report. Overall 95.5% of HTA studies either have published or will publish a monograph: 94% for those commissioned in 2002 or before and 98% for those commissioned after 2002.

Of the 287 projects for which there will be no report, the majority (221) were commissioned in 2002 or before. Reasons why projects failed to complete included: failure to recruit; issues concerning the organisation where the research was taking place; drug licensing issues; staffing issues; and access to data.

**Conclusions:** The percentage of HTA projects for which a monograph is published is high. The advantages of funding organisations requiring publication in their own journal include avoidance of publication bias and research waste; and enhancing accessibility of findings.

### Article summary

#### Article focus

- It has previously been suggested that potentially over 50% of biomedical studies funded are never published. Currently the literature on publication rates for funded studies is sparse.

#### Key messages

- This paper supplies data from a major UK funder of clinical trials (the NIHR HTA Programme) showing that 98% of its funded studies will publish in its own MEDLINE indexed journal.
- Benefits of a journal series run by the funder including high percentages of studies publishing findings, the opportunity for complete reporting and avoidance of publication bias are highlighted.

#### Strengths and limitations

- We considered a large sample of projects from a major UK research funder, over a period of 18 years
- Studies from earlier phase trials were not represented in this study

### Funding statement

This research was supported by the NIHR Evaluation, Trials and Studies Coordinating Centre through its Research on Research programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Department of Health, or of NETSCC.

### Competing interests statement

The authors have no competing financial interests; however, all of the authors are employed by the University of Southampton to work at least part time for NETSCC and NETSCC's reputation rests substantially on having managed the HTA Programme for the Department of Health for over 15 years.

In particular: RM is employed as the Head of NETSCC and has worked for NETSCC (and its predecessor organisation) in senior roles on and off since 1996. He was an editor of the Health Technology Assessment journal (1997-2007) and a founder editor for other journals in the new NIHR Journals Library (2011-12); AC has worked for the HTA Programme since 2005; ST worked for the HTA Programme 2005-2008.

### Study approval

This study did not require study ethics approval; it did not involve patients or clinical data.

### Introduction

It was stated by Chalmers and Glasziou (2009)<sup>1</sup> that worldwide, over US\$100 billion is invested per year in biomedical research. They went on to describe four stages at which waste of this resource may occur: choosing the wrong questions for research; doing studies that are unnecessary or poorly designed; failure to publish promptly or at all; and biased or unusable reports of research. This project responds primarily to the third stage of research waste identified; enabling accessible full publication. In their paper, Chalmers and Glasziou<sup>1</sup> suggested that potentially over 50% of clinical trials funded are never published in full. This data was obtained from a Cochrane review<sup>2</sup> which stated that "Less than half of all studies, and about 60% of randomized or controlled clinical trials, initially presented as summaries or abstracts at professional meetings are subsequently published as peer-reviewed journal articles".

It is vitally important that studies report in order to provide evidence to clinicians to inform practice, and policy makers to support them in decision making. There is currently a move towards open access to the data from publically funded research<sup>3,4</sup> in order to increase the returns on public investment; to increase transparency; to prevent duplication in research commissioning; to allow public scrutiny of the research process and inform patient and public decision making; and to make the results of trials available to the public including participants who have given their time to the study for public benefit.

It was also noted by Chalmers and Glasziou that publication bias leads to a systematic under reporting of studies with disappointing results, and that public access to the full results of all research remains an aspiration<sup>1</sup>. Other investigators have also found lower publication rates for

1  
2  
3 studies with negative results or indefinite conclusions<sup>2,5-8</sup>. The [National Institute for Health Research](#)  
4 [\(NIHR\) Health Technology Assessment \(HTA\) Programme](#) commissions and funds primary research  
5 and evidence synthesis on the effectiveness, costs and broader impact of healthcare treatments and  
6 tests for those who plan, provide or receive care in the NHS. It aspires to maximise return on  
7 investment by enabling, where possible, all funded projects to complete and publish, and  
8 maximising impact for money spent<sup>9</sup>.

9  
10  
11 The HTA Programme publishes a journal (Health Technology Assessment, known colloquially as the  
12 monograph series) which is available to all via the web and aims to publish a report for each project  
13 funded. The monograph is unique in that each publication focuses exclusively the final report of one  
14 study. Not only is publication encouraged, the agreement for the team to write and submit this final  
15 report is written into the contractual arrangement at the time of funding. The report is typically  
16 much longer than peer reviewed journal articles as teams are expected to publish full details of  
17 studies [\(such as a full description of the intervention\)](#) – essentially as an archive of the study;  
18 (irrespective of whether the results are positive, negative or indefinite), without limits on word  
19 count or length, in a high impact factor journal which is publically and freely available. [Authors are](#)  
20 [also encouraged to publish elsewhere to broaden dissemination of their findings, and there are](#)  
21 [other processes for the dissemination of Technology Assessment Reports.](#) This project aims to  
22 investigate the performance of the HTA Programme by assessing what percentage of HTA projects  
23 are published in the monograph series, and if they are not published what are the reasons?  
24  
25  
26  
27  
28  
29

## 30 **Methods**

31  
32  
33 For this study we selected a cohort of HTA projects for which the planned date for submission of  
34 their draft final report (DFR) for monograph publication was on or before 9th December 2011. We  
35 identified these projects from a proprietary database system used to manage the HTA and other  
36 NIHR research programmes.  
37  
38

39 We excluded from the sample: projects for which the reports were supplementing monographs  
40 already published; projects that were prospectively not considered suitable for the publication of a  
41 monograph e.g. working papers for [National Institute for health and Clinical Excellence \(NICE\)](#) or  
42 short briefing papers; and projects for which certain criteria needed to be met before the project  
43 commences e.g. projects relating to possible future H<sub>1</sub>N<sub>1</sub> pandemics.  
44  
45

46 To assure data quality, [NIHR Evaluation, Trials and Studies Coordinating Centre \(NETSCC\)](#) staff with  
47 responsibility for the publication process independently checked the records for studies where there  
48 was no publication. Similarly where data indicated that no DFR had been received this information  
49 was again checked with the team which should have received it.  
50  
51

52 All projects were categorised as either: primary research (typically randomised controlled trials);  
53 secondary research (mainly systematic reviews); HTA Technology Assessment Reports (TARs) (which  
54 identify, assess and synthesise research evidence from a number of healthcare interventions,  
55 providing estimates of relative effectiveness and cost effectiveness of a range of interventions); or  
56 NICE) TARs (similar to HTA TARs but prepared specifically for NICE). Projects were also categorised as:  
57  
58  
59  
60



1  
2  
3 (1) Projects for which a monograph has been published; (2) projects for which the DFR had been  
4 received but as yet there was no published monograph; (3) No DFR received and (4) project  
5 discontinued. The data were further sub-divided into those projects where the commissioning  
6 process started within the last 10 years (i.e. after 2002), and those where it began in 2002 or before.  
7

8  
9 When projects publish in the monograph series the draft final reports go through an editorial review  
10 process which is conducted between the editors, reviewers and authors. Reports are published in  
11 the HTA journal series if they are of a sufficiently high scientific quality as assessed by the referees  
12 and editors<sup>10</sup>. For projects which had not yet published, we needed to know whether a report would  
13 eventually be produced. Projects in this category were considered by a staff member (LT) with  
14 experience in editorial processes, ~~and~~ detailed knowledge of the projects concerned and knowledge  
15 of editorial decisions. They designated projects as either “will publish” or “will not publish”. This  
16 judgement was made using the following criteria. If at the end of the editorial process the editorial  
17 board of the HTA journal had deemed the report to be of “insufficient quality” to publish, this report  
18 was recorded as “will not publish”. If a report has been deemed as of sufficient quality to publish this  
19 was recorded as “will publish”. Data for “published” “will publish” or “will not publish” was originally  
20 obtained in July 2012 and updated on 8<sup>th</sup> March 2013. Each project was counted as one entity and  
21 the data were analysed by the calculation of percentages.  
22  
23  
24

25  
26 For projects which were not expected to publish, (or had been discontinued, or where no DFR had  
27 been received); we further investigated the reasons why by interrogating in-house electronic records  
28 and by referring to hard copy project files which contained detailed records of correspondence with  
29 the authors, at the time when the report was due. For projects where no DFR had been received a  
30 web search (searching Medline and Google scholar using authors’ names and key words); and a  
31 search of internal records was conducted to see if the results of the studies had been published  
32 elsewhere.  
33  
34

## 35 Results

36  
37  
38 Initial searches identified 642 projects (see Figure 1). Of these, 1 was excluded because it was a  
39 supplementary project following a monograph which had already been published; 3 because they  
40 related to potential future H<sub>1</sub>N<sub>1</sub> flu pandemics and required particular circumstances to occur before  
41 the project would begin; 1 as the report had been superseded by another; 5 as they had been  
42 included with another report under a different identification number. Four projects were not  
43 suitable for publication as monographs as they were very small and not suitable for publication  
44 alone; they had been commissioned to report by a different route; or were working papers for NICE.  
45 This left a cohort with a final total of 628 projects (201 primary research, 169 systematic reviews,  
46 110 HTA TARs and 148 NICE TARs).  
47  
48  
49

50  
51 For 3152 projects a DFR had been received but as yet there was no publication. After consultation  
52 with staff expert in this area, it was deemed that 1939 of these would eventually publish and 132  
53 would not (see Table 1). By March 2013 all of the 19 reports expected to publish were with the  
54 publisher and had been assigned dates by which it was anticipated that they would publish.  
55  
56  
57  
58  
59  
60

Table 1. DFR received, not yet published: “will publish” or “will not publish”

Type of research	Will publish	Will not publish	Total number for which DFR rec'd but not yet published
Primary research	<del>917</del>	<del>104</del>	<del>1928</del>
Systematic reviews	<del>28</del>	2	<del>410</del>
HTA TARs	<del>48</del>	0	<del>48</del>
NICE TARs	<del>46</del>	0	<del>46</del>
TOTALS	<del>139</del>	<del>123</del>	<del>3152</del>

In total ~~56482~~ projects had published a monograph, 2 studies had no DFR and 13 studies had been discontinued (see Table 2). For primary research studies, the reasons for discontinuation were mainly failure to recruit, e.g. in one case it was due to difficulties for the **principal investigator (PI)** caused by reorganisation within NHS institutions. For the systematic reviews and TARs, the reasons were either to do with drug licensing (NICE often requests TARs anticipating drug licencing, to inform future guidance, if **subsequently** the drug is not licensed, there is no need for a review, and NICE will cancel its request **consequently there will be no publication**). **Other reasons for discontinuation of studies were:** reliance being placed on access to data being allowed by a third party who then would not release the data; **and/or** issues around key staff leaving, or being unwell. A summary of results is given in Table 2.

Table 2. Numbers of studies published and research type

	PR	SR	HTA TAR	NICE TAR	Totals
Published	<del>17263</del>	<del>16357</del>	<del>1054</del>	<del>1420</del>	<del>58264</del> (92.789.3%)
No DFR rec'd	2	0	0	0	2 (0.3%)
Discontinued studies	8	2	1	2	13 (2.1%)
DFR rec'd – will publish	<del>917</del>	<del>28</del>	<del>48</del>	<del>46</del>	<del>319</del> (3.06.2%)
DFR rec'd – will not publish	<del>104</del>	2	0	0	<del>132</del> (1.92.1%)
Totals	201	169	110	148	628 (100%)

It was noticeable from the data that the majority of projects that did not publish were those commissioned early on in the history of the HTA Programme. The data shows that the vast majority of projects for which there will be no publication in the HTA monograph series were commissioned in 2002 or before (see **Figure 2Table 3**). There is a difference over time, where the percentage of

projects that publish rises from 94% to 98% and the numbers of projects not completing or not publishing falls from 6% to 2% after 2002.

More than half of the projects which will not publish (6 out of the 11 primary research studies and 1 of the 2 systematic reviews), and both projects that did not submit a DFR, were commissioned in 1993. This was before the HTA Programme had the current processes and procedures in place which have developed as the programme has matured. ~~and predates the existence of the National Coordinating Centre for Health Technology Assessment (NCCHTA) by three years. In fact some of the very early projects were not commissioned by the HTA programme; they were transferred over from a previous funding stream.~~ The results of the investigations as to why no monograph was to be published for projects for which a DFR had been submitted, are shown in Table 3. In the majority of cases (77%), this was because the draft report was of insufficient quality for publication as a monograph. Currently the HTA Programme operates editorial processes which work together with authors to bring reports up to publishable quality. For one project commissioned in 1993, we were unable to locate the paper files and so were unable to determine the reasons for non-publication.

Most of the projects (85%) which were not published as monographs were primary research projects.

**Table 3. Reasons why no monograph is to be published for projects for which a DFR had been submitted.**

	Draft final report (DFR) of insufficient quality	Study was only a pilot and was not therefore published as a monograph	Project commissioned in 1993, no records available	Totals
Primary research	9 (69%)	2 (15%)	0	11 (85%)
Systematic reviews	1 (8%)	0	1 (8%)	2 (15%)
Totals	10 (77%)	2 (15%)	1 (8%)	13

Considering the 2 projects where no DFR had been received; searches identified one peer reviewed paper. ~~and nine of~~ the 9 primary research studies where the DFRs received were of insufficient quality to publish as monographs, 6 of these projects had also published elsewhere in peer reviewed journals. Whether or not a draft final report is deemed to be of "insufficient quality" to publish is a judgement made by the editorial board of the HTA journal series. A monograph is expected to cover all aspects of the study concerned in detail (average word count approx. 50,000 words), in contrast journal articles are much shorter (approx. 3,000 words), less detailed, and covering only certain aspects of the study. The judgement concerning whether a pilot study can be published as a "stand alone" monograph, or possibly together with another study as a combined monograph, is made by the editorial board.

## Discussion

Overall the percentage of projects commissioned by the HTA Programme which publish in its journal is high, for those commissioned in 2002 or before 94% published, for those commissioned after 2002 the figure rises to 98%. This number is well in excess of the figure of 50% quoted by Chalmers and Glasziou<sup>1</sup> although it must be born in mind that their data related to studies initially presented as summaries or abstracts at professional meetings (which may include pilot or feasibility studies which do not progress to full studies), rather than commissioned projects, and so is likely to overestimate the publication rate. This rate is also higher than some other funders, for the NIH after a median of 51 months after trial completion, a third of trials remained unpublished<sup>11</sup>. ~~Little has been published by other research funders on publication rates of funded studies.~~

The strengths of this study were that it considered a large sample of projects from a major UK research funder, over a period of 18 years, encompassing a variety of research methodologies. Additionally in depth data were available on most of the projects to enable us to understand the reasons behind the statistical evidence. Weaknesses include: primary research projects considered within the cohort all related to a certain stage in health research and had to be within the remit of the Health Technology Assessment Programme which typically funds late phase clinical trials, investigating the effectiveness and cost effectiveness of a diverse range of health technologies (which may include drugs, devices, physical therapies, talking therapies, public health interventions, surgical procedures etc.). Consequently studies from earlier phase trials were not represented in this study. This work does not specifically consider the length of time to publication which is also pertinent<sup>12</sup>; however this question is being addressed in another study currently underway.

It is highly desirable that projects should publish final results for completed studies and the data presented here demonstrate a high level of project completion and publication. This is likely to be attributable to 3 particular elements of the programme: 1) selection of the right projects at the beginning, through using a “needs led” process to identify research questions of the most pressing interest to clinicians in the NHS. This also encourages buy-in from investigators and participants who are committed to answering important questions. 2) A robust monitoring process which ~~assists with timely delivery, budgets, etc.; and which~~ can anticipate which projects might fail and help to correct ~~problems as they arise~~ them. The majority of projects which have not published or will not publish were commissioned very early in the history of the HTA Programme. Current monitoring processes carefully monitor progress of projects, and action is taken to assist studies struggling with problems such as recruitment. It is likely that the current processes of the HTA Programme for both commissioning and monitoring have had a positive effect on the monograph publication rate.

Element 3) is the existence of the Health Technology Assessment journal. The high publication rate – a proxy for converting research funding into useful and accessible knowledge- demonstrates the benefits of such a system. Not only are the teams offered the opportunity and the space to publish studies in full, it is part of the contractual arrangement for funding ~~and a proportion of funds are~~ with-held until the report has been received. The journal publishes almost all projects regardless of results, thus minimising publication bias. ~~Authors are also encouraged to publish in other peer~~

reviewed journals to increase dissemination, however, the shorter length of these articles does not allow for the reporting of the detail presented in the monographs e.g. detailed descriptions of the intervention. Some studies elect to publish interim results in peer reviewed journals, however, it has been noted that the direction of effects reported in interim analyses and subsequent final analyses can vary<sup>8;13</sup>, the monograph series publishes final results in full. Teams associated with projects for which no monograph is to be published are strongly encouraged by the HTA Programme to publish in other journals. Of the two projects for which no DFR was submitted; one had published a peer reviewed paper elsewhere; and of the 9 primary studies for which no monograph was to be published 6 had published peer reviewed papers elsewhere. This would indicate that potential waste of resource had been minimised as at least some of the findings had been disseminated. The generalisability of these findings would only relate directly to another funding system with an in house journal, but the general principles of encouraging and facilitating publication would be generalisable to all funders.

~~It could be an i~~Interesting areas for future research could be: to compare the findings of this study which has used data from the HTA Programme with data from other funding streams or organisations, both within the UK and internationally; and an investigation of the dissemination profile of HTA projects in terms of journal publications and publically accessible reports.

Recommendations for future commissioning would include a requirement for funded projects to publish reports of final findings and for funders to facilitate this process.

### Acknowledgements

The authors wish to acknowledge Liz Trelvelick for help in determining whether or not projects were likely to publish in the future.

### Abbreviations

HTA: Health Technology Assessment

TAR: Technology Assessment Report

### Authors' contributions

The study was conceived and designed by ST, DW, RM, BM and AC, and undertaken by ST; ST led the writing guided by DW, AC and RM. All authors read and approved the final manuscript.

### Reference List

- 1
- 2
- 3 1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence.  
4 *The Lancet* 2009;**374**:86-9.
- 5
- 6 2. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts.  
7 *Cochrane Database of Systematic Reviews* 2007;**2**.
- 8
- 9 3. OECD Principles and Guidelines for Access to Research Data from Public Funding. Organisation  
10 for Economic Co-operation and Development . 2007.
- 11
- 12
- 13 4. National Institutes of Health Public Access. <http://publicaccess.nih.gov/> . 2012.
- 14 Ref Type: Generic
- 15
- 16 5. Krzyzanowska M, Pintilie M, Tannock I. Factors associated with failure to publish large  
17 randomized trials presented at an oncology meeting. *JAMA* 2003;**290**:495-501.
- 18
- 19 6. Song F, Parekh S, Hooper L, Loke YK, Ryder J. Dissemination and publication of research  
20 findings: an updated review of related biases. *Health Technol Assess* 2010;**14**.
- 21
- 22 7. Stern JM, Simes JR. Publication bias: evidence of delayed publication in a cohort study of  
23 clinical projects. *British Medical Journal* 1997;**315**:640-5.
- 24
- 25 8. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due  
26 to statistical significance or direction of trial results. *Cochrane Database of Systematic Reviews*  
27 2009;Art. No.: MR000006. DOI: 10.1002/14651858.MR000006.pub3.
- 28
- 29 9. Hanney S, Buxton M, Green C, Coulson D, Raftery J. An assessment of the impact of the NHS  
30 Health Technology Assessment Programme. *Health Technol Assess* 2007;**11**:1-200.
- 31
- 32 10. HTA Journal. Health Technology Assessment website. 2013.
- 33
- 34
- 35 11. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM *et al*. Publication of NIH funded trials  
36 registered in ClinicalTrials.gov: cross sectional analysis. *BMJ* 2011;**344**.
- 37
- 38 12. Takeda A, Loveman E, Harris P, Hartwell D, Welch K. Time to full publication of studies of anti-  
39 cancer medicines for breast cancer and the potential for publication bias: a short systematic  
40 review. *Health Technol Assess* 2010;**12**.
- 41
- 42 13. Harris P, Takeda A, Loveman E, Hartwell D. Time to full publication of studies of anticancer  
43 drugs for breast cancer, and the potential for publication bias. *International Journal of*  
44 *Technology Assessment in Health Care* 2010;**26**:110-6.
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1. Flow diagram of projects included in study





Figure 2 Percentages of projects commissioned either in 2002 or before, or after 2002; which do or do not publish in the HTA monograph series.



CONFIDENTIAL FOR REVIEW ONLY





**Publication rate for funded studies from a major UK health research funder: a cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002521.R2
Article Type:	Research
Date Submitted by the Author:	09-Apr-2013
Complete List of Authors:	Turner, Sheila; University of Southampton, NETSCC Wright, David; University of Southampton, NETSCC Maeso, Rebecca; University of Southampton, NETSCC Cook, Andrew; University of Southampton, Wessex Institute Milne, Ruairidh; University of Southampton, Wessex Institute
<b>Primary Subject Heading</b>:	Evidence based practice
Secondary Subject Heading:	Medical publishing and peer review
Keywords:	research waste, research funding, publication

SCHOLARONE™  
Manuscripts

For peer review only

## Title page

**Title:** Publication rate for funded studies from a major UK health research funder: a cohort study.

Turner S<sup>1a\*</sup>, Wright D<sup>1a</sup>, Maeso R<sup>2a</sup>, Cook A<sup>3b</sup> and Milne R<sup>4b</sup>.

<sup>a</sup>National Institute for Health Research  
Evaluation, Trials and Studies Coordinating Centre (NETSCC)  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

<sup>b</sup>Wessex Institute  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

\*Corresponding author, [s.turner@soton.ac.uk](mailto:s.turner@soton.ac.uk)  
Tel: +44(0)2380 595757 Fax: +44(0)2380 595639

<sup>1</sup>Senior research fellow; <sup>2</sup>Senior programme manager; <sup>3</sup>Consultant in Public Health Medicine and Fellow in Health Technology Assessment; <sup>4</sup>Director of the Wessex Institute and Head of NETSCC.

**Key words:** Health Technology Assessment, publication, research funding.

## Abstract

**Objectives:** This study aimed to investigate what percentage of National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme funded projects have published their final reports in the programme's journal Health Technology Assessment, and to explore reasons for non-publication.

**Design:** Retrospective cohort study.

**Setting:** Failure to publish findings from research is a significant area of research waste. It has previously been suggested that potentially over 50% of studies funded are never published.

**Participants:** All NIHR HTA projects with a planned submission date for their final report for publication in the journal series on or before 9th December 2011 were included.

**Primary and secondary outcome measures:** Projects were classified according to the type of research, whether they had published or not; and if not yet published, whether they would publish in the future or not. Reasons for non-publication were investigated.

**Results:** 628 projects were included: 582 (92.7%) had published a monograph; 19 (3.0%) were expected to publish a monograph; 13 (2.1%) were discontinued studies and would not publish; 12 (1.9%) submitted a report which did not lead to publication as a monograph; and two (0.3%) did not submit a report. Overall 95.7% of HTA studies either have published or will publish a monograph: 94% for those commissioned in 2002 or before and 98% for those commissioned after 2002.

Of the 27 projects for which there will be no report, the majority (21) were commissioned in 2002 or before. Reasons why projects failed to complete included: failure to recruit; issues concerning the organisation where the research was taking place; drug licensing issues; staffing issues; and access to data.

**Conclusions:** The percentage of HTA projects for which a monograph is published is high. The advantages of funding organisations requiring publication in their own journal include avoidance of publication bias and research waste.

## Article summary

### Article focus

- It has previously been suggested that potentially over 50% of biomedical studies funded are never published. Currently the literature on publication rates for funded studies is sparse.

### Key messages

- This paper supplies data from a major UK funder of clinical trials (the NIHR HTA Programme) showing that 98% of its funded studies will publish in its own MEDLINE indexed journal.
- Benefits of a journal series run by the funder including high percentages of studies publishing findings, the opportunity for complete reporting and avoidance of publication bias are highlighted.

### Strengths and limitations

- We considered a large sample of projects from a major UK research funder, over a period of 18 years
- Studies from earlier phase trials were not represented in this study.

## Introduction

It was stated by Chalmers and Glasziou (2009)<sup>1</sup> that worldwide, over US\$100 billion is invested per year in biomedical research. They went on to describe four stages at which waste of this resource may occur: choosing the wrong questions for research; doing studies that are unnecessary or poorly designed; failure to publish promptly or at all; and biased or unusable reports of research. This project responds primarily to the third stage of research waste identified; enabling accessible full publication. In their paper, Chalmers and Glasziou<sup>1</sup> suggested that potentially over 50% of clinical trials funded are never published in full. This data was obtained from a Cochrane review<sup>2</sup> which stated that “Less than half of all studies, and about 60% of randomized or controlled clinical trials, initially presented as summaries or abstracts at professional meetings are subsequently published as peer-reviewed journal articles”.

It is vitally important that studies report in order to provide evidence to clinicians to inform practice, and policy makers to support them in decision making. There is currently a move towards open access to the data from publically funded research<sup>3,4</sup> in order to increase the returns on public investment; to increase transparency; to prevent duplication in research commissioning; to allow public scrutiny of the research process and inform patient and public decision making; and to make

1  
2  
3 the results of trials available to the public including participants who have given their time to the  
4 study for public benefit.  
5

6  
7 It was also noted by Chalmers and Glasziou that publication bias leads to a systematic under  
8 reporting of studies with disappointing results, and that public access to the full results of all  
9 research remains an aspiration<sup>1</sup>. Other investigators have also found lower publication rates for  
10 studies with negative results or indefinite conclusions<sup>2,5-8</sup>. The National Institute for Health Research  
11 (NIHR) Health Technology Assessment (HTA) Programme commissions and funds primary research  
12 and evidence synthesis on the effectiveness, costs and broader impact of healthcare treatments and  
13 tests for those who plan, provide or receive care in the NHS. It aspires to maximise return on  
14 investment by enabling, where possible, all funded projects to complete and publish, and  
15 maximising impact for money spent<sup>9</sup>.  
16  
17

18 The HTA Programme publishes a journal (Health Technology Assessment, known colloquially as the  
19 monograph series) which is available to all via the web and aims to publish a report for each project  
20 funded. The monograph is unique in that each publication focuses exclusively the final report of one  
21 study. Not only is publication encouraged, the agreement for the team to write and submit this final  
22 report is written into the contractual arrangement at the time of funding. The report is typically  
23 much longer than peer reviewed journal articles as teams are expected to publish full details of  
24 studies (such as a full description of the intervention) – essentially as an archive of the study;  
25 (irrespective of whether the results are positive, negative or indefinite), without limits on word  
26 count or length, in a high impact factor journal which is publically and freely available. Authors are  
27 also encouraged to publish elsewhere to broaden dissemination of their findings, and there are  
28 other processes for the dissemination of Technology Assessment Reports. This project aims to  
29 investigate the performance of the HTA Programme by assessing what percentage of HTA projects  
30 are published in the monograph series, and if they are not published what are the reasons?  
31  
32  
33  
34  
35  
36

## 37 **Methods**

38  
39  
40 For this study we selected a cohort of HTA projects for which the planned date for submission of  
41 their draft final report (DFR) for monograph publication was on or before 9th December 2011. We  
42 identified these projects from a proprietary database system used to manage the HTA and other  
43 NIHR research programmes.  
44  
45

46 We excluded from the sample: projects for which the reports were supplementing monographs  
47 already published; projects that were prospectively not considered suitable for the publication of a  
48 monograph e.g. working papers for National Institute for health and Clinical Excellence (NICE) or  
49 short briefing papers; and projects for which certain criteria needed to be met before the project  
50 commences e.g. projects relating to possible future H<sub>1</sub>N<sub>1</sub> pandemics.  
51  
52

53 To assure data quality, NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) staff with  
54 responsibility for the publication process independently checked the records for studies where there  
55 was no publication. Similarly where data indicated that no DFR had been received this information  
56 was again checked with the team which should have received it.  
57  
58  
59  
60

1  
2  
3 All projects were categorised as either: primary research (typically randomised controlled trials);  
4 secondary research (mainly systematic reviews); HTA Technology Assessment Reports (TARs) (which  
5 identify, assess and synthesise research evidence from a number of healthcare interventions,  
6 providing estimates of relative effectiveness and cost effectiveness of a range of interventions); or  
7 NICE TARs (similar to HTA TARs but prepared specifically for NICE). Projects were also categorised as:  
8 (1) Projects for which a monograph has been published; (2) projects for which the DFR had been  
9 received but as yet there was no published monograph; (3) No DFR received and (4) project  
10 discontinued. The data were further sub-divided into those projects where the commissioning  
11 process started within the last 10 years (i.e. after 2002), and those where it began in 2002 or before.  
12  
13

14  
15 When projects publish in the monograph series the draft final reports go through an editorial review  
16 process which is conducted between the editors, reviewers and authors. Reports are published in  
17 the HTA journal series if they are of a sufficiently high scientific quality as assessed by the referees  
18 and editors<sup>10</sup>. For projects which had not yet published, we needed to know whether a report would  
19 eventually be produced. Projects in this category were considered by a staff member (LT) with  
20 experience in editorial processes, detailed knowledge of the projects concerned and knowledge of  
21 editorial decisions. They designated projects as either “will publish” or “will not publish”. This  
22 judgement was made using the following criteria. If at the end of the editorial process the editorial  
23 board of the HTA journal had deemed the report to be of “insufficient quality” to publish, this report  
24 was recorded as “will not publish”. If a report has been deemed as of sufficient quality to publish this  
25 was recorded as “will publish”. Data for “published” “will publish” or “will not publish” was originally  
26 obtained in July 2012 and updated on 8<sup>th</sup> March 2013. Each project was counted as one entity and  
27 the data were analysed by the calculation of percentages.  
28  
29  
30

31  
32 For projects which were not expected to publish, (or had been discontinued, or where no DFR had  
33 been received); we further investigated the reasons why by interrogating in-house electronic records  
34 and by referring to hard copy project files which contained detailed records of correspondence with  
35 the authors, at the time when the report was due. For projects where no DFR had been received a  
36 web search (searching Medline via Ovid, and Google Scholar®; using authors’ names and key words);  
37 and a search of internal records was conducted to see if the results of the studies had been  
38 published elsewhere.  
39  
40

## 41 Results

42  
43 Initial searches identified 642 projects (see Figure 1). Of these, one was excluded because it was a  
44 supplementary project following a monograph which had already been published; three because  
45 they related to potential future H<sub>1</sub>N<sub>1</sub> flu pandemics and required particular circumstances to occur  
46 before the project would begin; one as the report had been superseded by another; five as they had  
47 been included with another report under a different identification number. Four projects were not  
48 suitable for publication as monographs as they were very small and not suitable for publication  
49 alone; they had been commissioned to report by a different route; or were working papers for NICE.  
50 This left a cohort with a final total of 628 projects (201 primary research, 169 systematic reviews,  
51 110 HTA TARs and 148 NICE TARs).  
52  
53  
54  
55  
56  
57  
58  
59  
60

For 31 projects a DFR had been received but as yet there was no publication. After consultation with staff expert in this area, it was deemed that 19 of these would eventually publish and 12 would not (see Table 1). By March 2013 all of the 19 reports expected to publish were with the publisher and had been assigned dates by which it was anticipated that they would publish.

**Table 1. DFR received, not yet published: “will publish” or” will not publish”**

Type of research	Will publish	Will not publish	Total number for which DFR rec'd but not yet published
Primary research	9	10	19
Systematic reviews	2	2	4
HTA TARs	4	0	4
NICE TARs	4	0	4
<b>TOTALS</b>	<b>19</b>	<b>12</b>	<b>31</b>

In total 582 projects had published a monograph, two studies had no DFR and 13 studies had been discontinued (see Table 2). For primary research studies, the reasons for discontinuation were mainly failure to recruit, e.g. in one case it was due to difficulties for the principal investigator (PI) caused by reorganisation within NHS institutions. For the systematic reviews and TARs the reasons were either to do with drug licensing (NICE often requests TARs anticipating drug licencing, to inform future guidance, if subsequently the drug is not licensed, there is no need for a review, and NICE will cancel its request consequently there will be no publication). Other reasons for discontinuation of studies were: reliance being placed on access to data being allowed by a third party who then would not release the data; and issues around key staff leaving, or being unwell. A summary of results is given in Table 2.

**Table 2. Numbers of studies published and research type**

	PR	SR	HTA TAR	NICE TAR	Totals
<b>Published</b>	172	163	105	142	582 (92.7%)
<b>No DFR rec'd</b>	2	0	0	0	2 (0.3%)
<b>Discontinued studies</b>	8	2	1	2	13 (2.1%)
<b>DFR rec'd – will publish</b>	9	2	4	4	19 (3.0%)
<b>DRF rec'd – will not publish</b>	10	2	0	0	12 (1.9%)
<b>Totals</b>	<b>201</b>	<b>169</b>	<b>110</b>	<b>148</b>	<b>628 (100%)</b>

It was noticeable from the data that the majority of projects that did not publish were those commissioned early on in the history of the HTA Programme. The data shows that the vast majority of projects for which there will be no publication in the HTA monograph series were commissioned in 2002 or before (see Figure 2). There is a difference over time, where the percentage of projects that publish rises from 94% to 98% and the numbers of projects not completing or not publishing falls from 6% to 2% after 2002.

More than half of the projects which will not publish (six out of the 10 primary research studies and one of the two systematic reviews), and both projects that did not submit a DFR, were commissioned in 1993. This was before the HTA Programme had the current processes and procedures in place which have developed as the programme has matured. The results of the investigations as to why no monograph was to be published for projects for which a DFR had been submitted, are shown in Table 3. In the majority of cases (75%), this was because the draft report was of insufficient quality for publication as a monograph. Currently the HTA Programme operates editorial processes which work together with authors to bring reports up to publishable quality. For one project commissioned in 1993, we were unable to locate the paper files and so were unable to determine the reasons for non-publication. Most of the projects (83%) which were not published as monographs were primary research projects.

**Table 3. Reasons why no monograph is to be published for projects for which a DFR had been submitted.**

	<b>Draft final report (DFR) of insufficient quality</b>	<b>Study was only a pilot and was not therefore published as a monograph</b>	<b>Project commissioned in 1993, no records available</b>	<b>Totals</b>
<b>Primary research</b>	8 (67%)	2 (17%)	0	<b>10 (83%)</b>
<b>Systematic reviews</b>	1 (8%)	0	1 (8%)	<b>2 (17%)</b>
<b>Totals</b>	<b>9 (75%)</b>	<b>2 (17%)</b>	<b>1 (8%)</b>	<b>12</b>

Considering the two projects where no DFR had been received; searches identified one peer reviewed paper. Eight of the primary research studies where the DFRs received were of insufficient quality to publish as monographs, five of these projects had also published elsewhere in peer reviewed journals. Whether or not a draft final report is deemed to be of "insufficient quality" to publish is a judgement made by the editorial board of the HTA journal series. A monograph is expected to cover all aspects of the study concerned in detail (average word count approx. 50,000 words), in contrast journal articles are much shorter (approx. 3,000 words), less detailed, and



1  
2  
3 covering only certain aspects of the study. The judgement concerning whether a pilot study can be  
4 published as a “stand alone” monograph, or possibly together with another study as a combined  
5 monograph, is made by the editorial board.  
6  
7  
8

## 9 10 Discussion

11  
12  
13 Overall the percentage of projects commissioned by the HTA Programme which publish in its journal  
14 is high, for those commissioned in 2002 or before 94% published, for those commissioned after 2002  
15 the figure rises to 98%. This number is well in excess of the figure of 50% quoted by Chalmers and  
16 Glasziou<sup>1</sup> although it must be born in mind that their data related to studies initially presented as  
17 summaries or abstracts at professional meetings (which may include pilot or feasibility studies which  
18 do not progress to full studies), rather than commissioned projects, and so is likely to overestimate  
19 the publication rate. This rate is also higher than some other funders, for the National Institutes of  
20 Health in the United States, after a median of 51 months after trial completion, a third of trials  
21 remained unpublished<sup>11</sup>.  
22  
23

24  
25 The strengths of this study were that it considered a large sample of projects from a major UK  
26 research funder, over a period of 18 years, encompassing a variety of research methodologies.  
27 Additionally in depth data were available on most of the projects to enable us to understand the  
28 reasons behind the statistical evidence. Weaknesses include: primary research projects considered  
29 within the cohort all related to a certain stage in health research and had to be within the remit of  
30 the Health Technology Assessment Programme which typically funds late phase clinical trials,  
31 investigating the effectiveness and cost effectiveness of a diverse range of health technologies  
32 (which may include drugs, devices, physical therapies, talking therapies, public health interventions,  
33 surgical procedures etc.). Consequently studies from earlier phase trials were not represented in this  
34 study. This work does not specifically consider the length of time to publication which is also  
35 pertinent<sup>12</sup>; however this question is being addressed in another study currently underway.  
36  
37  
38

39  
40 It is highly desirable that projects should publish final results for completed studies and the data  
41 presented here demonstrate a high level of project completion and publication. This is likely to be  
42 attributable to three particular elements of the programme: 1) selection of the right projects at the  
43 beginning, through using a “needs led” process to identify research questions of the most pressing  
44 interest to clinicians in the NHS. This also encourages buy-in from investigators and participants who  
45 are committed to answering important questions. 2) A robust monitoring process which assists with  
46 timely delivery, budgets, etc.; and which can anticipate which projects might fail and help to correct  
47 problems as they arise. The majority of projects which have not published or will not publish were  
48 commissioned very early in the history of the HTA Programme. Current monitoring processes  
49 carefully monitor progress of projects, and action is taken to assist studies struggling with problems  
50 such as recruitment. It is likely that the current processes of the HTA Programme for both  
51 commissioning and monitoring have had a positive effect on the monograph publication rate.  
52  
53  
54

55  
56 Element 3) is the existence of the Health Technology Assessment journal. The high publication rate –  
57 a proxy for converting research funding into useful and accessible knowledge- demonstrates the  
58 benefits of such a system. Not only are the teams offered the opportunity and the space to publish  
59  
60

1  
2  
3 studies in full, it is part of the contractual arrangement for funding and a proportion of funds are  
4 with-held until the report has been received. The journal publishes almost all projects regardless of  
5 results, thus minimising publication bias. Authors are also encouraged to publish in other peer  
6 reviewed journals to increase dissemination, however, the shorter length of these articles does not  
7 allow for the reporting of the detail presented in the monographs e.g. detailed descriptions of the  
8 intervention. Some studies elect to publish interim results in peer reviewed journals, however, it has  
9 been noted that the direction of effects reported in interim analyses and subsequent final analyses  
10 can vary<sup>8;13</sup>, the monograph series publishes final results in full. Teams associated with projects for  
11 which no monograph is to be published are strongly encouraged by the HTA Programme to publish  
12 in other journals. Of the two projects for which no DFR was submitted; one had published a peer  
13 reviewed paper elsewhere; and of the eight primary studies for which no monograph was to be  
14 published five had published peer reviewed papers elsewhere. This would indicate that potential  
15 waste of resource had been minimised as at least some of the findings had been disseminated. The  
16 generalisability of these findings would only relate directly to another funding system with an in  
17 house journal, but the general principles of encouraging and facilitating publication would be  
18 generalisable to all funders.  
19  
20  
21  
22

23  
24 Interesting areas for future research could be: to compare the findings of this study which has used  
25 data from the HTA Programme with data from other funding streams or organisations, both within  
26 the UK and internationally. Additionally an investigation of the dissemination profile of HTA projects  
27 in terms of journal publications and publically accessible reports would be informative.  
28

29  
30 Recommendations for future commissioning would include funders making it a requirement for  
31 funded projects to publish reports of final findings; and for the funders to facilitate this process.  
32

### 33 **Acknowledgements**

34  
35 The authors wish to acknowledge Liz Trelvelick for help in determining whether or not projects were  
36 likely to publish in the future.  
37

### 38 **Abbreviations**

39  
40 HTA: Health Technology Assessment

41  
42 TAR: Technology Assessment Report  
43

### 44 **Authors' contributions**

45  
46 The study was conceived and designed by ST, DW, RM, BM and AC, and undertaken by ST; ST led the  
47 writing guided by DW, AC and RM. All authors read and approved the final manuscript.  
48

### 49 **Funding statement**

50  
51 This research was supported by the NIHR Evaluation, Trials and Studies Coordinating Centre through  
52 its Research on Research programme. The views and opinions expressed are those of the authors  
53 and do not necessarily reflect those of the Department of Health, or of NETSCC.  
54  
55  
56  
57  
58  
59  
60

### Competing interests statement

The authors have no competing financial interests; however, all of the authors are employed by the University of Southampton to work at least part time for NETSCC and NETSCC's reputation rests substantially on having managed the HTA Programme for the Department of Health for over 15 years.

In particular: RM is employed as the Head of NETSCC and has worked for NETSCC (and its predecessor organisation) in senior roles on and off since 1996. He was an editor of the Health Technology Assessment journal (1997-2007) and a founder editor for other journals in the new NIHR Journals Library (2011-12); AC has worked for the HTA Programme since 2005; ST worked for the HTA Programme 2005-2008.

### Study approval

This study did not require study ethics approval; it did not involve patients or clinical data.

### Data sharing

No additional unpublished data

### Reference List

1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *The Lancet* 2009;**374**:86-9.
  2. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. *Cochrane Database of Systematic Reviews* 2007;**2**.
  3. OECD Principles and Guidelines for Access to Research Data from Public Funding. Organisation for Economic Co-operation and Development . 2007.
  4. National Institutes of Health Public Access. <http://publicaccess.nih.gov/> . 2012.
- Ref Type: Generic
5. Krzyzanowska M, Pintilie M, Tannock I. Factors associated with failure to publish large randomized trials presented at an oncology meeting. *JAMA* 2003;**290**:495-501.
  6. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess* 2010;**14**.
  7. Stern JM, Simes JR. Publication bias: evidence of delayed publication in a cohort study of clinical projects. *British Medical Journal* 1997;**315**:640-5.
  8. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database of Systematic Reviews* 2009; Art. No.: MR000006. DOI: 10.1002/14651858.MR000006.pub3.
  9. Hanney S, Buxton M, Green C, et al. An assessment of the impact of the NHS Health Technology Assessment Programme. *Health Technol Assess* 2007;**11**:1-200.

- 1
- 2
- 3 10. HTA Journal. Health Technology Assessment website. 2013.
- 4
- 5
- 6 11. Ross JS, Tse T, Zarin DA, *et al*. Publication of NIH funded trials registered in ClinicalTrials.gov:  
7 cross sectional analysis. *BMJ* 2011;**344**.
- 8
- 9 12. Takeda A, Loveman E, Harris P, *et al*. Time to full publication of studies of anti-cancer  
10 medicines for breast cancer and the potential for publication bias: a short systematic review.  
11 *Health Technol Assess* 2010;**12**.
- 12
- 13 13. Harris P, Takeda A, Loveman E, *et al*. Time to full publication of studies of anticancer drugs for  
14 breast cancer, and the potential for publication bias. *International Journal of Technology*  
15 *Assessment in Health Care* 2010;**26**:110-6.
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only  
CONFIDENTIAL not for wider circulation  
view only

1  
2  
3 **Figure legends**  
4

5 **Figure 1. Flow diagram of projects included in study**  
6

7 **Figure 2 Percentages of projects commissioned either in 2002 or before, or**  
8 **after 2002; which do or do not publish in the HTA monograph series.**  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only  
CONFIDENTIAL not for wider circulation

## Title page

**Title:** Publication rate for funded studies from a major UK health research funder: a cohort study.

Turner S<sup>1a\*</sup>, Wright D<sup>1a</sup>, Maeso R<sup>2a</sup>, Cook A<sup>3b</sup> and Milne R<sup>4b</sup>.

<sup>a</sup>National Institute for Health Research  
Evaluation, Trials and Studies Coordinating Centre (NETSCC)  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

<sup>b</sup>Wessex Institute  
University of Southampton  
Alpha House, Enterprise Road  
Southampton SO16 7NS

\*Corresponding author, [s.turner@soton.ac.uk](mailto:s.turner@soton.ac.uk)  
Tel: +44(0)2380 595757 Fax: +44(0)2380 595639

<sup>1</sup>Senior research fellow; <sup>2</sup>Senior programme manager; <sup>3</sup>Consultant in Public Health Medicine and Fellow in Health Technology Assessment; <sup>4</sup>Director of the Wessex Institute and Head of NETSCC.

**Key words:** Health Technology Assessment, publication, research funding.

## Abstract

**Objectives:** This study aimed to investigate what percentage of [National Institute for Health Research \(NIHR\)](#) Health Technology Assessment (HTA) Programme funded projects have published their final reports in the programme's journal Health Technology Assessment, and to explore reasons for non-publication.

**Design:** ~~R~~retrospective cohort study.

**Setting:** Failure to publish findings from research is a significant area of research waste. It has previously been suggested that potentially over 50% of studies funded are never published.

**Participants:** All NIHR HTA projects with a planned submission date for their final report for publication in the journal series on or before 9th December 2011 were included.

**Primary and secondary outcome measures:** Projects were classified according to the type of research, whether they had published or not; and if not yet published, whether they would publish in the future or not. Reasons for non-publication were investigated.

**Results:** 628 projects were included: 582 (92.7%) had published a monograph; 19 (3.0%) were expected to publish a monograph; 13 (2.1%) were discontinued studies and would not publish; 12 (1.9%) submitted a report which did not lead to publication as a monograph; and ~~2~~two (0.3%) did not submit a report. Overall 95.7% of HTA studies either have published or will publish a monograph: 94% for those commissioned in 2002 or before and 98% for those commissioned after 2002.

Of the 27 projects for which there will be no report, the majority (21) were commissioned in 2002 or before. Reasons why projects failed to complete included: failure to recruit; issues concerning the organisation where the research was taking place; drug licensing issues; staffing issues; and access to data.

**Conclusions:** The percentage of HTA projects for which a monograph is published is high. The advantages of funding organisations requiring publication in their own journal include avoidance of publication bias and research waste; ~~and enhancing accessibility of findings.~~

### Article summary

#### Article focus

- It has previously been suggested that potentially over 50% of biomedical studies funded are never published. Currently the literature on publication rates for funded studies is sparse.

#### Key messages

- This paper supplies data from a major UK funder of clinical trials (the NIHR HTA Programme) showing that 98% of its funded studies will publish in its own MEDLINE indexed journal.
- Benefits of a journal series run by the funder including high percentages of studies publishing findings, the opportunity for complete reporting and avoidance of publication bias are highlighted.

#### Strengths and limitations

- We considered a large sample of projects from a major UK research funder, over a period of 18 years.
- Studies from earlier phase trials were not represented in this study.

### Funding statement

This research was supported by the NIHR Evaluation, Trials and Studies Coordinating Centre through its Research on Research programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Department of Health, or of NETSCC.

### Competing interests statement

The authors have no competing financial interests; however, all of the authors are employed by the University of Southampton to work at least part time for NETSCC and NETSCC's reputation rests substantially on having managed the HTA Programme for the Department of Health for over 15 years.

In particular: RM is employed as the Head of NETSCC and has worked for NETSCC (and its predecessor organisation) in senior roles on and off since 1996. He was an editor of the Health Technology Assessment journal (1997-2007) and a founder editor for other journals in the new NIHR Journals Library (2011-12); AC has worked for the HTA Programme since 2005; ST worked for the HTA Programme 2005-2008.

### Study approval

This study did not require study ethics approval; it did not involve patients or clinical data.

## Introduction

It was stated by Chalmers and Glasziou (2009)<sup>1</sup> that worldwide, over US\$100 billion is invested per year in biomedical research. They went on to describe four stages at which waste of this resource may occur: choosing the wrong questions for research; doing studies that are unnecessary or poorly designed; failure to publish promptly or at all; and biased or unusable reports of research. This project responds primarily to the third stage of research waste identified; enabling accessible full publication. In their paper, Chalmers and Glasziou<sup>1</sup> suggested that potentially over 50% of clinical trials funded are never published in full. This data was obtained from a Cochrane review<sup>2</sup> which stated that "Less than half of all studies, and about 60% of randomized or controlled clinical trials, initially presented as summaries or abstracts at professional meetings are subsequently published as peer-reviewed journal articles".

It is vitally important that studies report in order to provide evidence to clinicians to inform practice, and policy makers to support them in decision making. There is currently a move towards open access to the data from publically funded research<sup>3,4</sup> in order to increase the returns on public investment; to increase transparency; to prevent duplication in research commissioning; to allow public scrutiny of the research process and inform patient and public decision making; and to make the results of trials available to the public including participants who have given their time to the study for public benefit.



1  
2  
3 It was also noted by Chalmers and Glasziou that publication bias leads to a systematic under  
4 reporting of studies with disappointing results, and that public access to the full results of all  
5 research remains an aspiration<sup>1</sup>. Other investigators have also found lower publication rates for  
6 studies with negative results or indefinite conclusions<sup>2,5-8</sup>. The National Institute for Health Research  
7 (NIHR) Health Technology Assessment (HTA) Programme commissions and funds primary research  
8 and evidence synthesis on the effectiveness, costs and broader impact of healthcare treatments and  
9 tests for those who plan, provide or receive care in the NHS. It aspires to maximise return on  
10 investment by enabling, where possible, all funded projects to complete and publish, and  
11 maximising impact for money spent<sup>9</sup>.  
12  
13

14  
15 The HTA Programme publishes a journal (Health Technology Assessment, known colloquially as the  
16 monograph series) which is available to all via the web and aims to publish a report for each project  
17 funded. The monograph is unique in that each publication focuses exclusively the final report of one  
18 study. Not only is publication encouraged, the agreement for the team to write and submit this final  
19 report is written into the contractual arrangement at the time of funding. The report is typically  
20 much longer than peer reviewed journal articles as teams are expected to publish full details of  
21 studies (such as a full description of the intervention) – essentially as an archive of the study;  
22 (irrespective of whether the results are positive, negative or indefinite), without limits on word  
23 count or length, in a high impact factor journal which is publically and freely available. Authors are  
24 also encouraged to publish elsewhere to broaden dissemination of their findings, and there are  
25 other processes for the dissemination of Technology Assessment Reports. This project aims to  
26 investigate the performance of the HTA Programme by assessing what percentage of HTA projects  
27 are published in the monograph series, and if they are not published what are the reasons?  
28  
29  
30  
31  
32  
33

## 34 **Methods**

35  
36  
37 For this study we selected a cohort of HTA projects for which the planned date for submission of  
38 their draft final report (DFR) for monograph publication was on or before 9th December 2011. We  
39 identified these projects from a proprietary database system used to manage the HTA and other  
40 NIHR research programmes.  
41  
42

43 We excluded from the sample: projects for which the reports were supplementing monographs  
44 already published; projects that were prospectively not considered suitable for the publication of a  
45 monograph e.g. working papers for National Institute for health and Clinical Excellence (NICE) or  
46 short briefing papers; and projects for which certain criteria needed to be met before the project  
47 commences e.g. projects relating to possible future H<sub>1</sub>N<sub>1</sub> pandemics.  
48  
49

50 To assure data quality, NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) staff with  
51 responsibility for the publication process independently checked the records for studies where there  
52 was no publication. Similarly where data indicated that no DFR had been received this information  
53 was again checked with the team which should have received it.  
54  
55

56 All projects were categorised as either: primary research (typically randomised controlled trials);  
57 secondary research (mainly systematic reviews); HTA Technology Assessment Reports (TARs) (which  
58  
59  
60

1  
2  
3 identify, assess and synthesise research evidence from a number of healthcare interventions,  
4 providing estimates of relative effectiveness and cost effectiveness of a range of interventions); or  
5 NICE TARs (similar to HTA TARs but prepared specifically for NICE). Projects were also categorised as:  
6 (1) Projects for which a monograph has been published; (2) projects for which the DFR had been  
7 received but as yet there was no published monograph; (3) No DFR received and (4) project  
8 discontinued. The data were further sub-divided into those projects where the commissioning  
9 process started within the last 10 years (i.e. after 2002), and those where it began in 2002 or before.  
10  
11

12 When projects publish in the monograph series the draft final reports go through an editorial review  
13 process which is conducted between the editors, reviewers and authors. Reports are published in  
14 the HTA journal series if they are of a sufficiently high scientific quality as assessed by the referees  
15 and editors<sup>10</sup>. For projects which had not yet published, we needed to know whether a report would  
16 eventually be produced. Projects in this category were considered by a staff member (LT) with  
17 experience in editorial processes, detailed knowledge of the projects concerned and knowledge of  
18 editorial decisions. They designated projects as either “will publish” or “will not publish”. This  
19 judgement was made using the following criteria. If at the end of the editorial process the editorial  
20 board of the HTA journal had deemed the report to be of “insufficient quality” to publish, this report  
21 was recorded as “will not publish”. If a report has been deemed as of sufficient quality to publish this  
22 was recorded as “will publish”. Data for “published” “will publish” or “will not publish” was originally  
23 obtained in July 2012 and updated on 8<sup>th</sup> March 2013. Each project was counted as one entity and  
24 the data were analysed by the calculation of percentages.  
25  
26  
27  
28

29 For projects which were not expected to publish, (or had been discontinued, or where no DFR had  
30 been received); we further investigated the reasons why by interrogating in-house electronic records  
31 and by referring to hard copy project files which contained detailed records of correspondence with  
32 the authors, at the time when the report was due. For projects where no DFR had been received a  
33 web search (searching Medline [via Ovid](#), and Google [Scholar®](#); using authors’ names and key  
34 words); and a search of internal records was conducted to see if the results of the studies had been  
35 published elsewhere.  
36  
37  
38

## 39 Results

40  
41  
42 Initial searches identified 642 projects (see Figure 1). Of these, [one](#) was excluded because it was a  
43 supplementary project following a monograph which had already been published; [three](#) because  
44 they related to potential future H<sub>1</sub>N<sub>1</sub> flu pandemics and required particular circumstances to occur  
45 before the project would begin; [one](#) as the report had been superseded by another; [five](#) as they  
46 had been included with another report under a different identification number. Four projects were  
47 not suitable for publication as monographs as they were very small and not suitable for publication  
48 alone; they had been commissioned to report by a different route; or were working papers for NICE.  
49 This left a cohort with a final total of 628 projects (201 primary research, 169 systematic reviews,  
50 110 HTA TARs and 148 NICE TARs).  
51  
52  
53

54 For 31 projects a DFR had been received but as yet there was no publication. After consultation with  
55 staff expert in this area, it was deemed that 19 of these would eventually publish and 12 would not  
56  
57  
58  
59  
60

(see Table 1). By March 2013 all of the 19 reports expected to publish were with the publisher and had been assigned dates by which it was anticipated that they would publish.

**Table 1. DFR received, not yet published: “will publish” or “will not publish”**

Type of research	Will publish	Will not publish	Total number for which DFR rec'd but not yet published
Primary research	9	10	19
Systematic reviews	2	2	4
HTA TARs	4	0	4
NICE TARs	4	0	4
<b>TOTALS</b>	<b>19</b>	<b>12</b>	<b>31</b>

In total 582 projects had published a monograph, two studies had no DFR and 13 studies had been discontinued (see Table 2). For primary research studies, the reasons for discontinuation were mainly failure to recruit, e.g. in one case it was due to difficulties for the principal investigator (PI) caused by reorganisation within NHS institutions. For the systematic reviews and TARs the reasons were either to do with drug licensing (NICE often requests TARs anticipating drug licencing, to inform future guidance, if subsequently the drug is not licensed, there is no need for a review, and NICE will cancel its request consequently there will be no publication). Other reasons for discontinuation of studies were: reliance being placed on access to data being allowed by a third party who then would not release the data; and issues around key staff leaving, or being unwell. A summary of results is given in Table 2.

**Table 2. Numbers of studies published and research type**

	PR	SR	HTA TAR	NICE TAR	Totals
<b>Published</b>	172	163	105	142	582 (92.7%)
<b>No DFR rec'd</b>	2	0	0	0	2 (0.3%)
<b>Discontinued studies</b>	8	2	1	2	13 (2.1%)
<b>DFR rec'd – will publish</b>	9	2	4	4	19 (3.0%)
<b>DRF rec'd – will not publish</b>	10	2	0	0	12 (1.9%)
<b>Totals</b>	<b>201</b>	<b>169</b>	<b>110</b>	<b>148</b>	<b>628 (100%)</b>

It was noticeable from the data that the majority of projects that did not publish were those commissioned early on in the history of the HTA Programme. The data shows that the vast majority of projects for which there will be no publication in the HTA monograph series were commissioned in 2002 or before (see Figure 2). There is a difference over time, where the percentage of projects that publish rises from 94% to 98% and the numbers of projects not completing or not publishing falls from 6% to 2% after 2002.

More than half of the projects which will not publish (~~6~~<sup>six</sup> out of the 10 primary research studies and ~~1~~<sup>one</sup> of the ~~2~~<sup>two</sup> systematic reviews), and both projects that did not submit a DFR, were commissioned in 1993. This was before the HTA Programme had the current processes and procedures in place which have developed as the programme has matured. The results of the investigations as to why no monograph was to be published for projects for which a DFR had been submitted, are shown in Table 3. In the majority of cases (75%), this was because the draft report was of insufficient quality for publication as a monograph. Currently the HTA Programme operates editorial processes which work together with authors to bring reports up to publishable quality. For one project commissioned in 1993, we were unable to locate the paper files and so were unable to determine the reasons for non-publication. Most of the projects (83%) which were not published as monographs were primary research projects.

**Table 3. Reasons why no monograph is to be published for projects for which a DFR had been submitted.**

	Draft final report (DFR) of insufficient quality	Study was only a pilot and was not therefore published as a monograph	Project commissioned in 1993, no records available	Totals
Primary research	8 (67%)	2 (17%)	0	10 (83%)
Systematic reviews	1 (8%)	0	1 (8%)	2 (17%)
<b>Totals</b>	<b>9 (75%)</b>	<b>2 (17%)</b>	<b>1 (8%)</b>	<b>12</b>

Considering the ~~two~~<sup>two</sup> projects where no DFR had been received; searches identified one peer reviewed paper. Eight of the primary research studies where the DFRs received were of insufficient quality to publish as monographs, ~~five~~<sup>five</sup> of these projects had also published elsewhere in peer reviewed journals. Whether or not a draft final report is deemed to be of “insufficient quality” to publish is a judgement made by the editorial board of the HTA journal series. A monograph is expected to cover all aspects of the study concerned in detail (average word count approx. 50,000 words), in contrast journal articles are much shorter (approx. 3,000 words), less detailed, and covering only certain aspects of the study. The judgement concerning whether a pilot study can be

published as a “stand alone” monograph, or possibly together with another study as a combined monograph, is made by the editorial board.

## Discussion

Overall the percentage of projects commissioned by the HTA Programme which publish in its journal is high, for those commissioned in 2002 or before 94% published, for those commissioned after 2002 the figure rises to 98%. This number is well in excess of the figure of 50% quoted by Chalmers and Glasziou<sup>1</sup> although it must be born in mind that their data related to studies initially presented as summaries or abstracts at professional meetings (which may include pilot or feasibility studies which do not progress to full studies), rather than commissioned projects, and so is likely to overestimate the publication rate. This rate is also higher than some other funders, for the [National Institutes of Health in the United States, NIH](#) after a median of 51 months after trial completion, a third of trials remained unpublished<sup>11</sup>.

The strengths of this study were that it considered a large sample of projects from a major UK research funder, over a period of 18 years, encompassing a variety of research methodologies. Additionally in depth data were available on most of the projects to enable us to understand the reasons behind the statistical evidence. Weaknesses include: primary research projects considered within the cohort all related to a certain stage in health research and had to be within the remit of the Health Technology Assessment Programme which typically funds late phase clinical trials, investigating the effectiveness and cost effectiveness of a diverse range of health technologies (which may include drugs, devices, physical therapies, talking therapies, public health interventions, surgical procedures etc.). Consequently studies from earlier phase trials were not represented in this study. This work does not specifically consider the length of time to publication which is also pertinent<sup>12</sup>; however this question is being addressed in another study currently underway.

It is highly desirable that projects should publish final results for completed studies and the data presented here demonstrate a high level of project completion and publication. This is likely to be attributable to ~~three~~3 particular elements of the programme: 1) selection of the right projects at the beginning, through using a “needs led” process to identify research questions of the most pressing interest to clinicians in the NHS. This also encourages buy-in from investigators and participants who are committed to answering important questions. 2) A robust monitoring process which assists with timely delivery, budgets, etc.; and which can anticipate which projects might fail and help to correct problems as they arise. The majority of projects which have not published or will not publish were commissioned very early in the history of the HTA Programme. Current monitoring processes carefully monitor progress of projects, and action is taken to assist studies struggling with problems such as recruitment. It is likely that the current processes of the HTA Programme for both commissioning and monitoring have had a positive effect on the monograph publication rate.

Element 3) is the existence of the Health Technology Assessment journal. The high publication rate – a proxy for converting research funding into useful and accessible knowledge- demonstrates the benefits of such a system. Not only are the teams offered the opportunity and the space to publish studies in full, it is part of the contractual arrangement for funding and a proportion of funds are

with-held until the report has been received. The journal publishes almost all projects regardless of results, thus minimising publication bias. Authors are also encouraged to publish in other peer reviewed journals to increase dissemination, however, the shorter length of these articles does not allow for the reporting of the detail presented in the monographs e.g. detailed descriptions of the intervention. Some studies elect to publish interim results in peer reviewed journals, however, it has been noted that the direction of effects reported in interim analyses and subsequent final analyses can vary<sup>8;13</sup>, the monograph series publishes final results in full. Teams associated with projects for which no monograph is to be published are strongly encouraged by the HTA Programme to publish in other journals. Of the two projects for which no DFR was submitted; one had published a peer reviewed paper elsewhere; and of the **eight** primary studies for which no monograph was to be published **five** had published peer reviewed papers elsewhere. This would indicate that potential waste of resource had been minimised as at least some of the findings had been disseminated. The generalisability of these findings would only relate directly to another funding system with an in house journal, but the general principles of encouraging and facilitating publication would be generalisable to all funders.

Interesting areas for future research could be: to compare the findings of this study which has used data from the HTA Programme with data from other funding streams or organisations, both within the UK and internationally. ~~Additionally, and~~ an investigation of the dissemination profile of HTA projects in terms of journal publications and publically accessible reports **would be informative**.

Recommendations for future commissioning would include **funders making it** a requirement for funded projects to publish reports of final findings; and for **the** funders to facilitate this process.

### Acknowledgements

The authors wish to acknowledge Liz Trelvelick for help in determining whether or not projects were likely to publish in the future.

### Abbreviations

HTA: Health Technology Assessment

TAR: Technology Assessment Report


### Authors' contributions

The study was conceived and designed by ST, DW, RM, BM and AC, and undertaken by ST; ST led the writing guided by DW, AC and RM. All authors read and approved the final manuscript.

### Reference List


- 1
- 2
- 3
- 4
- 5 1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *The Lancet* 2009;**374**:86-9.
- 6
- 7
- 8 2. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. *Cochrane Database of Systematic Reviews* 2007;**2**.
- 9
- 10
- 11 3. OECD Principles and Guidelines for Access to Research Data from Public Funding. Organisation for Economic Co-operation and Development . 2007.
- 12
- 13
- 14
- 15 4. National Institutes of Health Public Access. <http://publicaccess.nih.gov/> . 2012.
- 16 Ref Type: Generic
- 17
- 18
- 19 5. Krzyzanowska M, Pintilie M, Tannock I. Factors associated with failure to publish large randomized trials presented at an oncology meeting. *JAMA* 2003;**290**:495-501.
- 20
- 21
- 22 6. Song F, Parekh S, Hooper L, Loke YK, Ryder J. Dissemination and publication of research findings: an updated review of related biases. *Health Technol Assess* 2010;**14**.
- 23
- 24
- 25 7. Stern JM, Simes JR. Publication bias: evidence of delayed publication in a cohort study of clinical projects. *British Medical Journal* 1997;**315**:640-5.
- 26
- 27
- 28 8. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database of Systematic Reviews* 2009;Art. No.: MR000006. DOI: 10.1002/14651858.MR000006.pub3.
- 29
- 30
- 31 9. Hanney S, Buxton M, Green C, Coulson D, Raftery J. An assessment of the impact of the NHS Health Technology Assessment Programme. *Health Technol Assess* 2007;**11**:1-200.
- 32
- 33
- 34
- 35 10. HTA Journal. Health Technology Assessment website. 2013.
- 36
- 37
- 38 11. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM *et al*. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. *BMJ* 2011;**344**.
- 39
- 40
- 41 12. Takeda A, Loveman E, Harris P, Hartwell D, Welch K. Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review. *Health Technol Assess* 2010;**12**.
- 42
- 43
- 44 13. Harris P, Takeda A, Loveman E, Hartwell D. Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias. *International Journal of Technology Assessment in Health Care* 2010;**26**:110-6.
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1. Flow diagram of projects included in study





**Figure 2 Percentages of projects commissioned either in 2002 or before, or after 2002; which do or do not publish in the HTA monograph series.**




CONFIDENTIAL FOR PEER REVIEW ONLY

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Figure 1. Flow diagram of projects included in study



90x116mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 2 Percentages of projects commissioned either in 2002 or before, or after 2002; which do or do not publish in the HTA monograph series.



CONFIDENTIAL

90x127mm (300 x 300 DPI)